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Abstract:
Objective 
Antidepressants are the most commonly prescribed psychiatric 
medication but concern has been raised about significant increases in 
their usage in high income countries. We aimed to quantify 
antidepressant prevalence, incidence, adherence and predictors of use in 
the adult population. 
Method 
The study record-linked administrative prescribing and morbidity data to 
the Generation Scotland cohort(GS:SFHS, N=11052), between 2009-16. 
Prevalence and incidence of any antidepressant use was determined. 
Antidepressant adherence was measured using Proportion of Days 
Covered and Medication Possession Ratio. Time-to-event analysis for 
antidepressant use, within 5 years, for antidepressant naïve GS:SFHS 
participants was performed to reveal patient-level predictors of use. 
Results 
Almost one third (28.0%, 95%CI 26.7-29.1) of the adults in our sample 
were prescribed at least one antidepressant in the five-year period 2012-
16. There was a 30.7% increase in annual prevalence between 2010-
2016. Incidence was 2.4(2.3-2.6)% per year. The majority of 
antidepressant episodes (56.5%) were greater than 9 months and 
http://mc.manuscriptcentral.com/jop
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adherence was generally high (66.8% with Proportion of Days Covered 
>80%). Only 11.6(10.2-13.0)% of antidepressant episodes were 
evidently reviewed by outpatient psychiatry. Predictors of new 
antidepressant use included history of affective disorder, being female, 
physical comorbidities, higher neuroticism scores, and lower cognitive 
function scores.   
Conclusions 
Antidepressant prevalence is greater than previously reported but 
incidence remains relatively stable. We found the majority of 
antidepressant episodes to be of relatively long duration with good 
estimated adherence. Increased long-term use among existing (and 
returning) users, along with wider ranges of indications for 
antidepressants, has significantly increased the prevalence of these 
medications.  
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Abstract (241 words)
Objective
Antidepressants are the most commonly prescribed psychiatric medication but concern has 
been raised about significant increases in their usage in high income countries. We aimed to 
quantify antidepressant prevalence, incidence, adherence and predictors of use in the adult 
population. 
Method
The study record-linked administrative prescribing and morbidity data to the Generation 
Scotland cohort(N=11052), between 2009-16. Prevalence and incidence of any antidepressant 
use was determined. Antidepressant adherence was measured using Proportion of Days 
Covered and Medication Possession Ratio. Time-to-event analysis for incident antidepressant 
use within 5 years of GS:SFHS recruitment was performed to reveal patient-level predictors 
of use. 
Results
Almost one third (28.0%, 95%CI 26.9-29.1) of the adults in our sample were prescribed at 
least one antidepressant in the five-year period 2012-16. There was a 36.2% increase in 
annual prevalence between 2010 and 2016. Incidence was 2.4(2.1-2.7)% per year. The 
majority of antidepressant episodes (57.6%) were greater than 9 months duration and 
adherence was generally high (69.0% with Proportion of Days Covered >80%). Predictors of 
new antidepressant use included history of affective disorder, being female, physical 
comorbidities, higher neuroticism scores, and lower cognitive function scores.  
Conclusions
Antidepressant prevalence is greater than previously reported but incidence remains 
relatively stable. We found the majority of antidepressant episodes to be of relatively long 
duration with good estimated adherence. Our study supports the hypothesis that increased 
long-term use among existing (and returning) users, along with wider ranges of indications 
for antidepressants, has significantly increased the prevalence of these medications.  
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Introduction
Antidepressants are the most commonly prescribed psychiatric medication and one of the 
most commonly prescribed medicines(Raymond et al., 2007; Olfson and Marcus, 2009). In 
the last 30 years, there has been a significant increase in antidepressant usage in high income 
countries(Ilyas and Moncrieff, 2012; Kendrick et al., 2015; Moore et al., 2009; Meijer et al., 
2004; Huijbregts et al., 2017; Lockhart and Guthrie, 2011; Munoz-Arroyo et al., 2006; Petty 
et al., 2006; Raymond et al., 2007; Exeter et al., 2009; Mojtabai and Olfson, 2014; Olfson 
and Marcus, 2009; Gonzalez-Lopez et al., 2015; Mars et al., 2017). Antidepressant 
consumption has reportedly increased 400% in the USA between 1998-2008(Pratt et al., 
2011), while antidepressant prescriptions in the UK increased twofold between 1995-
2011(Spence et al., 2014). Comparison of electronic prescribing records in five European 
countries suggests that antidepressant prescribing is comparatively high in the UK for adults 
aged 20-60, especially among females(Abbing-Karahagopian Huerta et al., 2014). In the 
USA, annual antidepressant prevalence for 2011 was estimated at 14.4%(Zhong et al., 2014) 
compared to an annual prevalence of depression in 2015 of 6.7%(National Institute of Mental 
Health, 2017b) and 2.7% for generalized anxiety disorder(National Institute of Mental 
Health, 2017a).  
The extent to which this rising tide of antidepressant prescribing is appropriate to clinical 
need is an area of ongoing controversy(Cruickshank et al., 2008; Lockhart and Guthrie, 2011; 
Reid I, 2013; Spence D, 2013). Antidepressant use has risen to a significantly greater degree 
than any rise in the prevalence of depression(Munoz-Arroyo et al., 2006) or of anxiety 
disorders(Bandelow and Michaelis, 2015). There is some evidence that illnesses treated by 
these medications, such as depression and anxiety, are now better recognised and treated at 
the primary care level(Kessler et al., 2005) and that GPs and patients are more willing to 
utilise antidepressant treatment for a wider range of indications(Trifiro et al., 2007; Kessler et 
al., 2005; Mojtabai and Olfson, 2014). It has also been argued that a greater antidepressant 
prescription rate does not correspond to an upsurge in incident cases, but rather represents a 
significant lengthening in the treatment period for existing users(Moore et al., 2009; 
Raymond et al., 2007; Mojtabai and Olfson, 2014; Mars et al., 2017; Reid I, 2013). Advisory 
bodies such as NICE and the WHO now recommend a minimum of six to nine months 
antidepressant treatment for moderate major depressive disorder (MDD) and two years or 
more treatment for chronic or relapsing illness(Petty et al., 2006; Reid I, 2013; Mars et al., 
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3
2017). This can serve to increase prescribing prevalence rates without necessarily increasing 
incidence. 
Nevertheless, concerns have been raised about a medicalisation of ordinary distress with 
antidepressants(Hollinghurst et al., 2005), and there are ongoing debates about the efficacy of 
antidepressants in mild-moderate depressive illness(Olfson and Marcus, 2009; Kirsch et al., 
2008; Cipriani et al., 2018). There has been increased attention to potential adverse effects of 
antidepressants(Bet et al., 2013), including discontinuation syndromes(Petty et al., 2006; 
Bosman et al., 2016), adverse physical outcomes in older adults(Coupland et al., 2011), risk 
of epilepsy(Hill et al., 2015), increased risk of suicidal thoughts in teens and young 
adults(Zhong et al., 2014) and increased rates of attempted suicide in the first 28 days after 
starting and stopping antidepressant treatment (Coupland et al., 2015). There are concerns 
that antidepressants are insufficiently reviewed by clinicians, leading to unnecessarily long 
treatment durations(Bosman et al., 2016; Johnson et al., 2012).  
Estimating the true prevalence and incidence of antidepressant usage is difficult and there 
have been few large population-based studies of antidepressant pharmaco-epidemiology. 
Many research studies of antidepressant use have relatively short follow-up 
periods(Huijbregts et al., 2017). A number of studies have used survey data(Lewer et al., 
2015; Mojtabai and Olfson, 2014; Olfson and Marcus, 2009), although such data is 
potentially susceptible to recall biases. Other studies have concentrated on use of 
antidepressants in depressive illness(Kendrick et al., 2015; Moore et al., 2009), which can 
underestimate the true population prevalence due to the wide range of indications for 
antidepressants. Record-linking existing population-based cohorts to routinely collected 
administrative health data presents an opportunity to improve pharmaco-epidemiological 
estimates of antidepressant use. 
Understanding patterns of antidepressant use is important in ensuring appropriate allocation 
of healthcare resources for patients and in maintaining effective monitoring systems for 
prescribing and adverse effects. In this study we have used a subset(N=11,052) of Generation 
Scotland, a large population- and family-based cohort of Scottish adults, with record-linkage 
to national prescribing data for the period 2009-2016. We aimed to provide a 
contemporaneous and population-scale quantification of patterns of antidepressant use, in 
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4
terms of prevalence, incidence, duration of prescribing episodes, adherence to medication, 
and patient-level predictors of use.   
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5
Method 
Study Sample
We used the Generation Scotland: Scottish Family Health Study (GS:SFHS) population- and 
family-based cohort (N=21,474) of adult volunteers across Scotland, recruited February 
2006-March 2011, which has been described elsewhere (Smith et al., 2006; Smith et al., 
2013)(for overview, see Supplementary Materials). Recruitment to GS:SFHS began in 2006, 
but prescribing data was available only from 2009 onwards. We therefore restricted our 
analysis to those individuals in GS:SFHS recruited from September 2009 to March 2011 
(N=11052, 6518 females and 4534 males, see Figure 1 and Supplementary Table S1). This 
ensured that all individuals had at least six months of prescribing data prior to their enrolment 
in GS:SFHS, with which to ascertain their pre-enrolment medication usage, and at least five 
years’ worth of prescribing data following their enrolment. Of these, 96.5% had medication 
records available in the prescribing data (the remainder were presumably not using prescribed 
medication), which compared with 95.6% for the whole GS:SFHS cohort. 
Like GS:SFHS as a whole, the study sample had a higher proportion of females (59%) and 
was of older age (mean 49 males SD 15.3, 49 females SD 15.2) compared to the Scottish 
general population (mean 37 males, 39 females, 2001 census)(Smith et al., 2013). The study 
sample was typically healthier and more affluent that the general Scottish population, 
nevertheless 32.9% of individuals lived in areas with socio-economic deprivation worse than 
the average(median), as measured by the Scottish Index of Multiple Deprivation(Smith et al., 
2013). 99% of the study sample was of white ethnicity (Scottish population 98%).
Phenotyping in Generation Scotland
Sociodemographic information recorded in GS:SFHS included sex, age, smoking status and 
relationship status, collected by pre-clinic questionnaire at recruitment (see Table S1, 
Supplementary Materials). Lifetime history of affective disorder (major depressive 
disorder(MDD) and bipolar disorder) was obtained using the Structured Clinical Interview 
for DSM-IV disorders(SCID)(Smith et al., 2013). This was operationalised in the pre-clinic 
questionnaire using two screening questions, with those who answered affirmatively going on 
be interviewed with the mood sections of the SCID. The screening questions were : “Have 
you ever seen anyone for emotional or psychiatric problems?” and “Was there ever a time 
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6
when you, or someone else, thought you should see someone because of the way you were 
feeling or acting?”. 
Cognitive tests included the digit symbol substitution test from the Wechsler Adult 
Intelligence Scale III (Wechsler D, 1998b), logical memory from the Wechsler Memory 
Scale III (Wechsler D, 1998a), and verbal fluency(Lezak, 1995). From these tests, we derived 
a measure of cognitive ability (g) as the first unrotated principal component, explaining 44% 
of the variance in scores(Marioni et al., 2014). 
Psychological distress was measured using the General Health Questionnaire (GHQ-28, 
Likert scoring)(Goldberg and Hillier, 1979). An overall score of 24 or greater has been used 
to identify cases of potential psychiatric disorder(Swallow, 2003). Neuroticism was measured 
using the Eysenck Personality Questionnaire Short Form Revised (EPQ-SF)(Eysenck and 
Eysenck, 1964). The EPQ-SF is a self-report questionnaire consisting of twelve Yes/No 
questions which are used to assess neuroticism (on a scale 0-12, with higher scores 
representing greater neuroticism). The EPQ-SF has been validated with other quantitative 
measures of neuroticism(Gow et al., 2005) with high reliability(Eysenck et al., 1985).  
Schizotypal traits were elicited using the Schizotypy Personality Questionnaire (SPQ)(Raine, 
1991). Socioeconomic deprivation was determined using the Scottish Index of Multiple 
Deprivation 2009 (SIMD)(Scottish Government, 2009).
Prescribing Data and Linkage
All Scottish citizens registered with a General Practitioner are assigned a unique identifier, 
the Community Health Index(CHI). This was used to deterministically record-link GS:SFHS 
participants to the national Prescribing Information System (PIS) administered by NHS 
Services Scotland Information Services Division(ISD)(Alvarez-Madrazo et al., 2016). PIS is 
a database of all Scottish NHS medications prescribed by GPs, nurses, dentists, pharmacists, 
and hospitals, where the medication was dispensed in the community. There is no 
prescription charge in Scotland since 2011. Hospital-dispensed prescriptions and over-the-
counter medications are not included. We obtained PIS prescribing data for April 2009 (the 
earliest date available) to December 2016. 
We additionally linked to the Scottish Morbidity Records (SMR00, SMR01 and SMR04) to 
obtain information about appointments with outpatient or inpatient secondary mental health 
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7
services during the period of study. The SMR records Scotland-wide outpatient, daycase and 
inpatient hospital (including psychiatric hospital) attendances per annum since 1981. We also 
linked to ISD data on mortality to determine which participants of GS:SFHS had died during 
the period of follow up and excluded these from our estimates where relevant. 
Identification of Psychiatric Medication Usage
The PIS data allows medication to be identified by approved drug name and/or associated 
British National Formulary(BNF)(Joint Formulary Committee, 2012) paragraph code. 
Medication indication is not recorded in PIS. PIS records medication type, dose, dosage 
instructions and number of defined daily doses (DDDs) for each medication. DDDs are a 
measure for standardising drug doses(WHO, 2011). For a small part of the dataset (4.9%) the 
dosage instructions were missing, and these were imputed (as described in the Supplementary 
Materials). 
We defined antidepressants (drugs for depression) as any drug included in BNF Chapter 4.3, 
entitled “Antidepressant Drugs”.  Sel ctive Serotonin Reuptake Inhibitors (SSRIs) were 
identified via BNF Section 4.3.3, Tricyclic Antidepressants (TCAs) via Section 4.3.1 and 
Selective Serotonin and Noradrenaline Reuptake Inhibitors(SNRIs) were identified from 
Section 4.3.4 (venlafaxine and duloxetine). We defined  ‘other antidepressants’ as including 
Monoamine Oxidase Inhibitors (MAOIs), identified via Section 4.3.2, and the remaining 
drugs within Section 4.3.4. To comply with Neuroscience-based Nomenclature(Worley, 
2017), a glossary of the mechanisms of action of each of the medications included in our 
study is provided in Table S5 of the Supplementary Material. 
We recorded antidepressant medication use as any dispensed prescription during the period 
analysed(which was the defined 5 year period 2012-2016 in some analyses and 1-5 years 
following individual GS:SFHS recruitment in others, as specified).  We also applied 
additional thresholds : in the majority of our analyses, and unless otherwise stated, we 
repeated our analyses excluding low dose (<75mg) amitriptyline prescriptions, as this 
medication and dosage is most commonly prescribed for non-psychiatric purposes (such as 
neuropathic pain, migraine and tension headache) and frequently for very short periods(Mars 
et al., 2017). With regard to antidepressant dosage, we produced estimates for antidepressants 
of all dosages, and separate estimates for antidepressants prescriptions which met at least 
minimum BNF dose recommendations for MDD (for adult or older adults as appropriate). 
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Prevalence and Incidence
For each one-year period, we calculated the number of patients receiving any antidepressant 
prescription. Annual prevalence was calculated as the number of living cohort members using 
at least one antidepressant prescription that year, as a proportion of the reference sample. We 
also calculated the period prevalence for 2012-16 and the period prevalence for 
antidepressant use in the five years following each individual’s enrolment in GS:SFHS.  
To calculate incidence, we defined antidepressant naïve individuals as those who (a) were not 
on any antidepressant at the time of enrolment to GS:SFHS, or the 6 months preceding, and  
(b) did not report antidepressant use on the medication self-report questionnaire included in 
GS:SFHS, and (c) did not have a history of MDD or bipolar disorder on the SCID (which 
would indicate likely, although not definite, previous antidepressant use) (d) did not have a 
previous diagnosis of affective or anxiety disorders in the Scottish Morbidity Record(SMR) 
prior to GS:SFHS recruitment. We calculated incidence on the basis of the number of new 
users from the antidepressant naïve group, divided by the number of cohort members without 
antidepressant use in the preceding year. 
Identification of Antidepressant Episodes and Adherence
We defined a drug treatment “episode” as consecutively dispensed prescriptions with a 
maximum interval between prescribing events of 90 days after the expected end date of the 
previous prescription, based on the dosage instructions(Gardarsdottir et al., 2010). We used 
90 days as the cut-off point as it is unusual in the UK to be given more than three months 
medication per prescribing event (for sensitivity analyses with alternative cut-off points see 
Table S6 in Supplementary Material). We did not include new episodes which began in the 
second half of 2016, as it was not possible to estimate their duration. We defined “long-term” 
antidepressant use as a consecutive antidepressant episode of at least 15 months (based on 
three months for acute treatment, nine months for continuation-phase treatment, and three 
months for discontinuation, following the approach of Keyloun (Keyloun et al., 2017)). 
We calculated medication adherence using the Medication Possession Ratio (MPR) and 
Proportion of Days Covered (PDC) metrics(Keyloun et al., 2017). MPR is defined as the sum 
of the day’s supply for all dispensed medication in the episode divided by the number of days 
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in the period, expressed as a percentage. PDC is defined as the number of days in a 
prescribing episode that are adequately “covered” by the preceding prescribing event, divided 
by the number of days in the episode, expressed as a percentage. Compared to MPR, PDC is 
generally regarded as a more conservative and preferred measure. Satisfactory adherence was 
defined as MPR or PDC >80% for the antidepressant episode(Keyloun et al., 2017).    
Statistical Analysis
All analyses were carried out using R version 3.2.3. Prevalence and incidence rates were 
expressed as percentages, together with 95% confidence intervals. These estimates were 
reweighted by age and sex to reflect the Scottish population, using the 2011 Scottish 
census(Scottish Government, 2011). Age-sex reweighting was performed using the direct 
standardisation method using the R package “epitools”. 
As GS:SFHS is a family based cohort, which could lead to biases due to the hierarchical 
structure of the data, we used a mixed model implementation of Cox regression (with inter-
relatedness controlled using pedigree as a random effect), using the R package “coxme”. We 
controlled for potential confounding related to the recruitment area from which each 
participant was enrolled using a categorical variable in the model. 
There was some (range 0.8-5.1%) missing data for some of the variables collected in 
Generation Scotland(see Supplementary Material including Table S2) and this missing data 
was imputed using the Multiple Imputation by Chained Equations method implemented in 
the R package “mice”. The final estimates were the result of pooling n=100 imputed datasets, 
using Rubin’s rules(van Buuren, 2012). Further details on the imputation, and the results of 
complete case analysis, are provided in the Supplementary Material. P values were corrected 
for multiple testing using the False Discovery Rate(FDR) method. 
Results 
Sample
The basic demographics of the sample compared to the Scottish population are available in 
the Supplementary Material(Table S1). An antidepressant was prescribed at least once to 
3742 individuals (33.9(95%CI 33.0-34.8)%) of the 11,052 in our study between April 2009 
and December 2016. There was a 36.2% increase in the annual prevalence of antidepressant 
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prescribing between 2010 (age-sex reweighted prevalence 12.7(95%CI 12.0-13.5)%) and 
2016 (17.3(16.5-18.3)%). During the seven year period 2010-16, 79,857 antidepressant 
prescriptions were dispensed (22 for every antidepressant user in GS:SFHS). 
Low dose amitriptyline prescriptions(<75mg) accounted for 18.3% of prescriptions and 943 
individuals (25%) were only prescribed low dose amitriptyline. Discounting low dose 
amitriptyline, there were 2624 antidepressant users with a mean of 1.8 antidepressant 
episodes (range 1-9, S.D. 1.1) during the period 2010-16. Although we had no data on 
specific indication, 84.2% of these episodes reached a dosage equivalent to at least the 
required BNF minimum for the treatment of Major Depressive Disorder. 
The most commonly prescribed class of antidepressants was Selective Serotonin Reuptake 
Inhibitors(SSRIs), accounting for 54% of prescriptions in 2010 and 52.7% in 2016 (65.6% 
and 64% respectively if low dose amitriptyline excluded). The proportion of Serotonin and 
Noradrenaline Reuptake Inhibitors(SNRIs) prescribed increased from 9.1% in 2010 to 10.9% 
in 2016, and the proportion of other antidepressants (such as mirtazapine) increased from 
6.7% to 8.3% during the same period. The proportion of Tricyclic Antidepressants(TCAs) 
was 27.8% in 2016, or 12.3% if low dose amitriptyline excluded. 
Period Prevalence 2012-16
The 5-year 2012-2016 age-sex reweighted period prevalence of antidepressant use was 
28.0(95%CI 26.9-29.1)% for the cohort. With low dose amitriptyline excluded, the 
prevalence was 20.8 (19.9-21.8)% (see Table 1). The five-year prevalence was considerably 
higher among females, 34.9(33.3-36.6)%, than males, 20.4(19.0-22.0)%. There was a 
bimodal distribution of antidepressant use by age, with 2012-16 period prevalence highest in 
the 45-54 age group for all antidepressants(33.3(31.3-35.3%)) and a second peak in the 75+ 
age group(33.3(28.8-38.8)%) (Figure 2). 
Prevalence of Antidepressant Prescribing in One to Five Years Follow-Up
In the first year following each individual’s GS:SFHS enrolment, 11.2(95%CI 10.6-11.8)% 
of the cohort had at least one antidepressant prescription(excluding low dose amitriptyline, as 
does all analysis in this section), which increased to 20.8(20.0-21.6)% after five years.
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Among those with history of recurrent MDD on recruitment, 52.4(48.5-56.2)% were 
prescribed at least one antidepressant within 1 year following GS recruitment and for bipolar 
disorder the proportion was 46.2(30.4-62.6)%. For those with no history of MDD on 
recruitment, 6.9(6.5-7.5)% were prescribed at least one antidepressant within one year – or 
2.5(2.2-2.9)% if those already on antidepressants at recruitment were excluded. 
Among those with a GHQ-28 Likert score of 24 or above at the time of GS:SFHS 
recruitment, 31.7(95% CI 29.4-34.1)% had at least one antidepressant prescription within 1 
year. Among the antidepressant naïve subgroup at the time of GS:SFHS recruitment, 6.6(5.1-
8.6)% of those with a Likert score of >=24 were prescribed antidepressants within 1 year and 
9.2(4.1-18.6)% of those scoring over three standard deviations above the mean on the GHQ 
depression subscale (subscale D) were prescribed an antidepressant within 1 year. 
Incidence of Antidepressant Prescribing 2012-16
The age-sex reweighted incidence of antidepressant prescribing was 2.4(2.1-2.7)% per year 
for all antidepressants and 1.6(1.4-1.9)% if low dose amitriptyline is excluded. Incidence was 
greater in females 2.7(2.4-3.2)% than males 2.0(1.6-2.5)%. 
77.1% of incident antidepressant users were commenced on an SSRI, with 11.9% on a TCA 
(low dose amitriptyline excluded), 4.0% on a serotonin and noradrenaline reuptake 
inhibitor(SNRI) and 7.0% on other antidepressants(especially mirtazapine). The most 
common individual medication for new users was citalopram (39.9%), followed by fluoxetine 
(21.6%) and sertraline (14.2%). Less than 1% were commenced on paroxetine and none on 
reboxetine or MAOIs. The most common tricyclic antidepressant for new users was 
nortriptyline (3.9%) followed by higher dose amitriptyline(3.0%). 
Antidepressant Episodes
In the five years period 2012-16, 2385 individuals used antidepressants and we defined 3595 
antidepressant episodes(low dose amitriptyline excluded). Some 86.6% (n=3112) of episodes 
reached at least minimum dose required for treatment of MDD (although actual indication 
was not available). We allowed antidepressant switching or combination during episodes, 
with the majority of episodes(79.3%) having just one antidepressant, 13.6% having two and 
7.1% having three or more(range 3-6). 
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Over half (57.6%) of antidepressant episodes were of 9 months or greater and 44.8% met our 
15-month criteria for long term use, with the majority of antidepressant users (57.7%) having 
a least one episode of long term duration. Nevertheless, approximately one tenth (10.6%) of 
episodes were of less than 30 days duration and a further 12.6% were of 31-90 days, meaning 
that approximately one quarter of episodes were less than three months duration. 
Adherence
For the 3595 antidepressant episodes between 2012-16(n=2385 individuals), the mean 
Medication Possession Ratio(MPR) per antidepressant episode was 96.0% (range 11-412) 
and the mean Proportion of Days Covered(PDC) was 84.9% (range 11-100). Using PDC >= 
80% as defining adherence, 69.0% of antidepressant episodes were adherent, when using 90 
days as the cut-off point between antidepressant episodes (for sensitivity analysis see Table 
S6 in Supplementary Materials). M an PDC was similar across medication classes (SSRI 
84.5%, TCA 84.3%, SNRI 83.2%, MAOI 77.3%, other 83.9%, see Table S6 in 
Supplementary Materials). 
Polypharmacy 
Other medications that were co-prescribed with antidepressants during an antidepressant 
episode were determined, with simultaneous use on at least three occasions being classed as 
“regular” use.  Anxiolytics (medicines for anxiety) were co-prescribed to 34.1% of 
antidepressant users (16.4% regularly), including benzodiazepines 23.6% (10.7% regularly) 
and “Z-drugs”(the benzodiazepine-receptor agonists zopiclone, zolpidem and zaleplon) 
18.9% (7.6% regularly). Pregabalin or gabapentin (alpha-2 delta calcium channel blockers 
often used to treat anxiety and neuropathic pain as well as epilepsy) were co-prescribed to 
12.8% users (8.9% regularly). Antipsychotics (medicines to treat psychosis) were co-
prescribed to 6.8% antidepressant users (5.1% regularly). Lithium compounds or sodium 
valproate, which are also used to treat mood disorders, were co-prescribed to 1.6% (1.4% 
regularly). Opiate-based analgesic (pain relieving) medications were co-prescribed to 22% of 
antidepressant users (13.3% regularly), compared to a general five-year prevalence of 15.6% 
(Figure 3).  Opioid use was also higher in those with a history of bipolar disorder 
(33.3%,regular 18.5%) and recurrent MDD (27.8%, regular 17.3%) on GS:SFHS recruitment, 
compared to those with no affective disorder history (20.5%, regular 12.3%).  
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Use of psychiatric services
Using record linkage to hospital data, 10.0(8.9-11.2)% of antidepressant users in the five 
years following GS:SFHS enrolment, who were prescribed at least the minimum BNF 
recommended dosage for MDD,  had a psychiatric outpatient appointment during at least one 
of their antidepressant treatment episodes. Some 1.8(1.4-2.5)% of antidepressant users were 
admitted to psychiatric hospital during at least one episode of antidepressant treatment. 
Predictors of antidepressant use - time to event analysis 
We performed time-to-antidepressant-use Cox regression analysis for the five years 
following individual GS:SFHS enrolment, excluding those individuals already on 
antidepressants (Figure 4 and Table 2). Female gender was predictive of commencing 
antidepressants in the multivariable model (Hazard Ratio(HR)=1.74, 95% CI 1.53-1.98, 
pFDR<0.0001). Lower SIMD deprivation status was associated with antidepressant use in 
univariate analysis (and in complete case analysis, see Supplementary Table S3) but was not 
significant in the multivariable model. Neuroticism (HR 1.12,1.09-1.14 per unit, 
pFDR<0.0001), previous history of unemployment(HR=1.24, 1.06-1.45, pFDR=0.02)  and 
smoking status (current smokers HR 1.57(1.34-1.84, pFDR <0.0001) were also positively 
associated with antidepressant use, whereas cognitive function (g) scores were negatively 
associated (HR 0.89, 0.85-0.93, pFDR 0.001). Multiple physical comorbidities (3+) were 
positively associated with antidepressant use (HR 1.85,1.33-2.57, pFDR 0.002). The most 
predictive factor for antidepressant use was previous history of affective disorder on 
GS:SFHS recruitment, with history of a single episode of MDD having a hazard ratio of 2.22 
(1.85-2.67, pFDR<0.0001). 
Discussion 
Summary of Main Results
In this study, we demonstrate an increase in antidepressant usage in this UK cohort, with an 
estimated 17.3% of the adult population using antidepressants in 2016, an increase of nearly 
one third(36.2%) on 2010(see Supplementary Table S4). We have found that, even if low 
dose amitriptyline use is discounted, one fifth of our sample (20.8%) has been prescribed an 
antidepressant at least once between 2012-16. The prescribing of antidepressants continues to 
be dominated by the SSRI class, but we observed a rise in the proportion of SNRIs, and other 
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antidepressants such as mirtazapine, prescribed. This is an interesting trend and may be 
further stimulated by future revisions of clinical guidance, which may recategorize 
mirtazapine as a first-line treatment in psychiatric disorders such as major depression, leading 
to further increases in prevalence of use and interest in the efficacy and safety profile of 
mirtazapine and other non-SSRI antidepressants(Coupland et al., 2015; Cipriani et al., 2018). 
Our findings accord with recent UK data which has found that antidepressant prescribing is 
the highest ever at 64.7m prescriptions for England in 2016(NHS Digital, 2017). However, in 
this study we also found a reweighted incidence for new antidepressant users of just 2.4%, 
and a duration for antidepressant episodes of in excess of 15 months in nearly half of 
episodes identified. This supports the hypothesis of increased longer-term use by regular 
antidepressant users driving much of the increased prevalence of antidepressants we report.  
Our study also found that adhe ence to antidepressants was relatively high, meeting the more 
conservative PDC threshold adherence of 80% in 69.0% of cases. 
We found that history of affective disorder, multiple physical comorbidities, and being 
female, were the most predictive of antidepressant use. We also report an interesting 
association between neuroticism and antidepressant use, with considerably greater incident 
antidepressant use in the upper tertile of EPQ-SF neuroticism scores(Figure 4). Neuroticism 
is a personality trait with significant clinical overlap with psychiatric disorder(Smith et al., 
2016), which is relatively straightforward to measure prospectively, and our results suggest 
that it could be a useful predictor of future antidepressant usage. A recent study in older 
adults (Steffens et al., 2018)has found that neuroticism may be also associated with lower 
remission rates of antidepressant-treated depression. We also found that cognitive function 
had an inverse association with antidepressant use, in line with previous research indicating 
an association between cognitive impairment and MDD(Marazziti et al., 2010). 
With this study methodology we cannot judge definitely whether the increasing 
antidepressant prevalence we found is appropriate to clinical indication.  The prevalence of 
prescribing we report should be seen in the context of not only the prevalence of MDD, but 
the prevalence of anxiety disorders, eating disorders, sexual disorders, sleep disorders and 
other indications for antidepressant medication. Nevertheless, it has also been argued that 
current rates of antidepressant treatment may still not identify all those most likely to benefit 
(Kendrick et al., 2005). The National Health and Nutrition Examination Surveys 2005-
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08(Pratt et al., 2011) found that only one third of those with severe depressive symptoms 
were on antidepressant therapy, and less than half of those taking multiple antidepressants 
had seen a mental health professional in the past year. In our study, we found that, among 
those antidepressant naïve individuals with the highest psychiatric ‘caseness’ according to 
GHQ scores in Generation Scotland, just 6.6% were prescribed an antidepressant within one 
year of follow-up, and less than 10% of those with the highest severe depression caseness 
(three standard deviations on the GHQ-28 D subscale) were prescribed an antidepressant 
within one year.  This might indicate potential unmet clinical need for antidepressants, 
although such a conclusion should be approached with caution as GHQ is a measure of 
psychiatric distress at one timepoint, and higher GHQ scores do not necessarily indicate 
requirement for antidepressants. 
It has also been previously argued that antidepressants are insufficiently reviewed by 
clinicians, leading to unnecessarily long treatment durations(Bosman et al., 2016; Johnson et 
al., 2012). The European Study of the Epidemiology of Mental Disorders (ESEMed) 
demonstrated that 63.5% of those with mood disorders had not consulted health services in 
the previous 12 months(Alonso J, 2004), with similar findings in the US National 
Comorbidity Survey Replication(Wang et al., 2005).  We found that only a small minority of 
antidepressant users are being reviewed in outpatient psychiatry, suggesting that the majority 
of antidepressant monitoring takes place in primary care. The high prevalence of 
antidepressant use we report suggests that there may be scope for increasing the rate of 
medication reviews for long-term antidepressant users in primary (and secondary) care, with 
consideration of managed discontinuation of treatment. This can help manage the risks 
associated with prolonged antidepressant exposure when a sustained recovery from illness 
has been achieved. 
Among medications frequently co-prescribed with antidepressants, the most common 
psychiatric class was anxiolytics, especially benzodiazepines and “Z-drugs”. We found that 
the co-prescribing of analgesic and opiate medication was appreciably higher in 
antidepressant users, especially those with a history of recurrent depression and bipolar 
disorder. An association between depression and pain has been previously 
described(McIntosh et al., 2016) and could be related to altered pain sensitivity in depressed 
states and comorbidity of depression with painful conditions.
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Comparison With Previous Studies 
A previous prescribing database study of the Tayside population of Scotland 
(n=325,000)(Lockhart and Guthrie, 2011) found an increase in prevalence from 8.0% in 
1995/96 to 13.4% in 2006/07. The standardised rate for 2006-07 antidepressants was 13.1% 
(SSRIs 7.9%, TCAs 5.2%, other antidepressants 1.9%) compared to the reweighted 2016 
rates of 17.3% (10.5%, 5.8%, 3.2%) found in our study. Analysis of the UK Clinical Practice 
Research Datalink (CPRD, N=1,524,201) found that 23% of individuals were prescribed at 
least one antidepressant between 1995 and 2001(Mars et al., 2017). 
Results from the US National Health and Nutrition Examination Survey (NHANES) found a 
2009-10 annual prevalence of 10.4%(Mojtabai and Olfson, 2014), with 67.4% reporting use 
for 24 months or longer, and 17.1% for <6 months. Incidence was estimated at 2.55% (per 
100 individuals per year) in comparison with our estimated incidence of 2.4%. In this US 
study, 32.5% of antidepressant users had visited a mental health professional in the previous 
year, compared with 10.0% in our UK-based study. 
A prescription database study in British Columbia conducted in 2004(Raymond et al., 2007) 
found a prevalence of 7.2% and found that lower socioeconomic groupings and lowest 
income groupings had higher prevalences of antidepressant use. In our time-to-event analysis 
we found the lowest SIMD quintiles were associated with antidepressant use in univariate 
analysis but not in the multivariable model.  
A recent study of routine general practice care data in a cohort based in Amsterdam 
(n=156,620) found 43.7% of antidepressant users were long-term users(Huijbregts et al., 
2017), which is similar to our own finding of 44.8%. 
Strengths and Limitations
This study benefitted from the relatively large population-based GS:SFHS cohort and the 
availability of structured clinical interview data alongside quantitative measures of non-
specific psychiatric morbidity and numerous demographic, socio-economic and 
psychological variables. The national prescribing and morbidity data to which it was linked 
was of high fidelity (with a capture rate in excess of 95%) and, being nationally based, 
reduced the chance of individuals being lost to follow up during the study period due to, for 
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example, moving their GP practice. We were also able to record the date of dispensing as 
well as prescribing, and whether the medication was collected. By applying a longitudinal 
retrospective design rather than a cross-sectional approach, this study increased the potential 
for accurate measurement of the pharmaco-epidemiological variables. 
However, by using a cohort study as its basis, this analysis is also susceptible to selection and 
confounding biases. Another significant limitation is the lack of details of the indication of 
medication use in the PIS prescribing data(as with many other prescribing databases based on 
routinely collected administrative data). In GS:SFHS, previous history of affective disorder 
was collected via screening using the SCID, but we were not able to determine ongoing and 
subsequent psychiatric diagnoses in the period studied following GS:SFHS recruitment. It is 
likely that a proportion of those individuals with no previous history of affective disorder 
were subsequently diagnosed with such, or that other psychiatric disorders such as anxiety 
disorders were the indication for later antidepressant treatment. GS:SFHS did not provide 
data on baseline history of anxiety disorders to complement the SCID-derived history of 
affective disorders. We were also not able to determine the extent to which severity of 
psychiatric symptoms or level of functional impairment determines antidepressant usage. 
Prescribing data is also an imperfect proxy for m dication use, given that the medication may 
not be taken (primary noncompliance) or may not be used as directed (secondary 
noncompliance). Noncompliance to antidepressant medication has been previously estimated 
at 50%(Haynes et al., 2008).  The PIS prescribing data only covered prescriptions issued in 
the community, and therefore may underestimate true prevalence and treatment duration, 
although it would be expected that most antidepressant users commenced in hospital would 
continue medication in the community. A further limitation of our study being based on 
routinely collected administrative prescribing data is that it is also not possible to determine 
the extent to which the antidepressant prescribing we recorded was appropriate to clinical 
need or consistent with treatment guidelines.
Although we attempted to apply stringent criteria for incident use of antidepressants - using 
prescription data, linked morbidity data, self-report and objectively measured history of 
affective disorder to screen antidepressant naïve cohort members - we may still have falsely 
identified some previous antidepressant users as incident cases, particularly as we did not 
have data preceding April 2009. 
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Our Cox regression analysis of predictors of antidepressant use within 5 years was 
necessarily restricted by the variables available to us in GS:SFHS. We were able to derive 
effect sizes for numerous variables previously associated with antidepressant use, such as 
history of affective disorder, medical comorbidities and female gender. However, due to the 
limited diagnostic information available in GS:SFHS we were not able to quantify the 
association between non-affective psychiatric disorders such as anxiety disorders (which are 
likely to be significantly predictive) and antidepressant use. The conclusions of our time-to-
event analysis need to be placed in the context of the variables available in our model. 
The cohort was also for adults only, thereby not including antidepressant use among the 
under 18s, and the overall population prevalence and incidence would be expected to be 
lower than our figures since children are prescribed antidepressants less frequently. 
Future Directions and Clinical Implications 
We found that antidepressant prevalence was higher than previously reported for the UK, but 
that incidence remains relatively stable. This suggests that increased antidepressant 
prevalence is driven by longer treatment durations and good levels of adherence, and 
previous users returning to medication for a wider range of indications, rather than an 
upsurge in incident cases. Our study also demonstrates the utility of record-linking 
administrative health data to population-based cohorts to provide enhanced pharmaco-
epidemiological estimates of prevalence, incidence and adherence. We also found significant 
relationships between neuroticism and cognitive function for antidepressant use, even when 
affective disorder was controlled for. These tests are relatively easy to administer and could 
provide useful to clinicians in constructing predictive models of clinical risk. 
More research is required to investigate the clinical appropriateness of antidepressant 
prescribing. Our research suggests that the vast majority of antidepressant prescribing and 
medication review takes place in the primary care setting in the UK.  Primary care will 
necessarily therefore remain the focal point for future efforts to improve antidepressant 
prescribing practices, monitoring of adherence and adverse effects, and managed 
discontinuation of treatment when clinically appropriate. 
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Pharmaco-epidemiology of Antidepressant Exposure in a UK Cohort Record-Linkage 
Study
Hafferty JD, Wigmore EM, Howard DM, Adams MJ, Clarke T-K, Campbell AI, MacIntyre 
DJ, Nicodemus KK, Lawrie SM, Porteous DJ, McIntosh AM
Abstract (241 words)
Objective
Antidepressants are the most commonly prescribed psychiatric medication but concern has 
been raised about significant increases in their usage in high income countries. We aimed to 
quantify antidepressant prevalence, incidence, adherence and predictors of use in the adult 
population. 
Method
The study record-linked administrative prescribing and morbidity data to the Generation 
Scotland cohort(N=11052), between 2009-16. Prevalence and incidence of any antidepressant 
use was determined. Antidepressant adherence was measured using Proportion of Days 
Covered and Medication Possession Ratio. Time-to-event analysis for incident antidepressant 
use within 5 years of GS:SFHS recruitment was performed to reveal patient-level predictors 
of use. 
Results
Almost one third (28.0%, 95%CI 26.9-29.1) of the adults in our sample were prescribed at 
least one antidepressant in the five-year period 2012-16. There was a 36.2% increase in 
annual prevalence between 2010 and 2016. Incidence was 2.4(2.1-2.7)% per year. The 
majority of antidepressant episodes (57.6%) were greater than 9 months duration and 
adherence was generally high (69.0% with Proportion of Days Covered >80%). Predictors of 
new antidepressant use included history of affective disorder, being female, physical 
comorbidities, higher neuroticism scores, and lower cognitive function scores.  
Conclusions
Antidepressant prevalence is greater than previously reported but incidence remains 
relatively stable. We found the majority of antidepressant episodes to be of relatively long 
duration with good estimated adherence. Our study supports the hypothesis that increased 
long-term use among existing (and returning) users, along with wider ranges of indications 
for antidepressants, has significantly increased the prevalence of these medications.  
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Introduction
Antidepressants are the most commonly prescribed psychiatric medication and one of the 
most commonly prescribed medicines(Raymond et al., 2007; Olfson and Marcus, 2009). In 
the last 30 years, there has been a significant increase in antidepressant usage in high income 
countries(Ilyas and Moncrieff, 2012; Kendrick et al., 2015; Moore et al., 2009; Meijer et al., 
2004; Huijbregts et al., 2017; Lockhart and Guthrie, 2011; Munoz-Arroyo et al., 2006; Petty 
et al., 2006; Raymond et al., 2007; Exeter et al., 2009; Mojtabai and Olfson, 2014; Olfson 
and Marcus, 2009; Gonzalez-Lopez et al., 2015; Mars et al., 2017). Antidepressant 
consumption has reportedly increased 400% in the USA between 1998-2008(Pratt et al., 
2011), while antidepressant prescriptions in the UK increased twofold between 1995-
2011(Spence et al., 2014). Comparison of electronic prescribing records in five European 
countries suggests that antidepressant prescribing is comparatively high in the UK for adults 
aged 20-60, especially among females(Abbing-Karahagopian Huerta et al., 2014). In the 
USA, annual antidepressant prevalence for 2011 was estimated at 14.4%(Zhong et al., 2014) 
compared to an annual prevalence of depression in 2015 of 6.7%(National Institute of Mental 
Health, 2017b) and 2.7% for generalized anxiety disorder(National Institute of Mental 
Health, 2017a).  
The extent to which this rising tide of antidepressant prescribing is appropriate to clinical 
need is an area of ongoing controversy(Cruickshank et al., 2008; Lockhart and Guthrie, 2011; 
Reid I, 2013; Spence D, 2013). Antidepressant use has risen to a significantly greater degree 
than any rise in the prevalence of depression(Munoz-Arroyo et al., 2006) or of anxiety 
disorders(Bandelow and Michaelis, 2015). There is some evidence that illnesses treated by 
these medications, such as depression and anxiety, are now better recognised and treated at 
the primary care level(Kessler et al., 2005) and that GPs and patients are more willing to 
utilise antidepressant treatment for a wider range of indications(Trifiro et al., 2007; Kessler et 
al., 2005; Mojtabai and Olfson, 2014). It has also been argued that a greater antidepressant 
prescription rate does not correspond to an upsurge in incident cases, but rather represents a 
significant lengthening in the treatment period for existing users(Moore et al., 2009; 
Raymond et al., 2007; Mojtabai and Olfson, 2014; Mars et al., 2017; Reid I, 2013). Advisory 
bodies such as NICE and the WHO now recommend a minimum of six to nine months 
antidepressant treatment for moderate major depressive disorder (MDD) and two years or 
more treatment for chronic or relapsing illness(Petty et al., 2006; Reid I, 2013; Mars et al., 
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2017). This can serve to increase prescribing prevalence rates without necessarily increasing 
incidence. 
Nevertheless, concerns have been raised about a medicalisation of ordinary distress with 
antidepressants(Hollinghurst et al., 2005), and there are ongoing debates about the efficacy of 
antidepressants in mild-moderate depressive illness(Olfson and Marcus, 2009; Kirsch et al., 
2008; Cipriani et al., 2018). There has been increased attention to potential adverse effects of 
antidepressants(Bet et al., 2013), including discontinuation syndromes(Petty et al., 2006; 
Bosman et al., 2016), adverse physical outcomes in older adults(Coupland et al., 2011), risk 
of epilepsy(Hill et al., 2015), increased risk of suicidal thoughts in teens and young 
adults(Zhong et al., 2014) and increased rates of attempted suicide in the first 28 days after 
starting and stopping antidepressant treatment (Coupland et al., 2015). There are concerns 
that antidepressants are insufficiently reviewed by clinicians, leading to unnecessarily long 
treatment durations(Bosman et al., 2016; Johnson et al., 2012).  
Estimating the true prevalence and incidence of antidepressant usage is difficult and there 
have been few large population-based studies of antidepressant pharmaco-epidemiology. 
Many research studies of antidepressant use have relatively short follow-up 
periods(Huijbregts et al., 2017). A number of studies have used survey data(Lewer et al., 
2015; Mojtabai and Olfson, 2014; Olfson and Marcus, 2009), although such data is 
potentially susceptible to recall biases. Other studies have concentrated on use of 
antidepressants in depressive illness(Kendrick et al., 2015; Moore et al., 2009), which can 
underestimate the true population prevalence due to the wide range of indications for 
antidepressants. Record-linking existing population-based cohorts to routinely collected 
administrative health data presents an opportunity to improve pharmaco-epidemiological 
estimates of antidepressant use. 
Understanding patterns of antidepressant use is important in ensuring appropriate allocation 
of healthcare resources for patients and in maintaining effective monitoring systems for 
prescribing and adverse effects. In this study we have used a subset(N=11,052) of Generation 
Scotland, a large population- and family-based cohort of Scottish adults, with record-linkage 
to national prescribing data for the period 2009-2016. We aimed to provide a 
contemporaneous and population-scale quantification of patterns of antidepressant use, in 
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terms of prevalence, incidence, duration of prescribing episodes, adherence to medication, 
and patient-level predictors of use.   
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Method 
Study Sample
We used the Generation Scotland: Scottish Family Health Study (GS:SFHS) population- and 
family-based cohort (N=21,474) of adult volunteers across Scotland, recruited February 
2006-March 2011, which has been described elsewhere (Smith et al., 2006; Smith et al., 
2013)(for overview, see Supplementary Materials). Recruitment to GS:SFHS began in 2006, 
but prescribing data was available only from 2009 onwards. We therefore restricted our 
analysis to those individuals in GS:SFHS recruited from September 2009 to March 2011 
(N=11052, 6518 females and 4534 males, see Figure 1 and Supplementary Table S1). This 
ensured that all individuals had at least six months of prescribing data prior to their enrolment 
in GS:SFHS, with which to ascertain their pre-enrolment medication usage, and at least five 
years’ worth of prescribing data following their enrolment. Of these, 96.5% had medication 
records available in the prescribing data (the remainder were presumably not using prescribed 
medication), which compared with 95.6% for the whole GS:SFHS cohort. 
Like GS:SFHS as a whole, the study sample had a higher proportion of females (59%) and 
was of older age (mean 49 males SD 15.3, 49 females SD 15.2) compared to the Scottish 
general population (mean 37 males, 39 females, 2001 census)(Smith et al., 2013). The study 
sample was typically healthier and more affluent that the general Scottish population, 
nevertheless 32.9% of individuals lived in areas with socio-economic deprivation worse than 
the average(median), as measured by the Scottish Index of Multiple Deprivation(Smith et al., 
2013). 99% of the study sample was of white ethnicity (Scottish population 98%).
Phenotyping in Generation Scotland
Sociodemographic information recorded in GS:SFHS included sex, age, smoking status and 
relationship status, collected by pre-clinic questionnaire at recruitment (see Table S1, 
Supplementary Materials). Lifetime history of affective disorder (major depressive 
disorder(MDD) and bipolar disorder) was obtained using the Structured Clinical Interview 
for DSM-IV disorders(SCID)(Smith et al., 2013). This was operationalised in the pre-clinic 
questionnaire using two screening questions, with those who answered affirmatively going on 
be interviewed with the mood sections of the SCID.  given the Structured Clinical Interview 
for DSM-IV disorders(Smith et al., 2013). The screening questions were : “Have you ever 
seen anyone for emotional or psychiatric problems?” and “Was there ever a time when you, 
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or someone else, thought you should see someone because of the way you were feeling or 
acting?”. 
Cognitive tests included the digit symbol substitution test from the Wechsler Adult 
Intelligence Scale III (Wechsler D, 1998b), logical memory from the Wechsler Memory 
Scale III (Wechsler D, 1998a), and verbal fluency(Lezak, 1995). From these tests, we derived 
a measure of cognitive ability (g) as the first unrotated principal component, explaining 44% 
of the variance in scores(Marioni et al., 2014). 
Psychological distress was measured using the General Health Questionnaire (GHQ-28, 
Likert scoring)(Goldberg and Hillier, 1979). An overall score of 24 or greater has been used 
to identify cases of potential psychiatric disorder(Swallow, 2003). Neuroticism was measured 
using the Eysenck Personality Questionnaire Short Form Revised (EPQ-SF)(Eysenck and 
Eysenck, 1964). The EPQ-SF is a self-report questionnaire consisting of twelve Yes/No 
questions which are used to assess neuroticism (on a scale 0-12, with higher scores 
representing greater neuroticism). The EPQ-SF has been validated with other quantitative 
measures of neuroticism(Gow et al., 2005) with high reliability(Eysenck et al., 1985).  
Schizotypal traits were elicited using the Schizotypy Personality Questionnaire (SPQ)(Raine, 
1991). Socioeconomic deprivation was determined using the Scottish Index of Multiple 
Deprivation 2009 (SIMD)(Scottish Government, 2009).
Prescribing Data and Linkage
All Scottish citizens registered with a General Practitioner are assigned a unique identifier, 
the Community Health Index(CHI). This was used to deterministically record-link GS:SFHS 
participants to the national Prescribing Information System (PIS) administered by NHS 
Services Scotland Information Services Division(ISD)(Alvarez-Madrazo et al., 2016). PIS is 
a database of all Scottish NHS medications prescribed by GPs, nurses, dentists, pharmacists, 
and hospitals, where the medication was dispensed in the community. There is no 
prescription charge in Scotland since 2011. Hospital-dispensed prescriptions and over-the-
counter medications are not included. We obtained PIS prescribing data for April 2009 (the 
earliest date available) to December 2016. 
We additionally linked to the Scottish Morbidity Records (SMR00, SMR01 and SMR04) to 
obtain information about appointments with outpatient or inpatient secondary mental health 
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services during the period of study. The SMR records Scotland-wide outpatient, daycase and 
inpatient hospital (including psychiatric hospital) attendances per annum since 1981. We also 
linked to ISD data on mortality to determine which participants of GS:SFHS had died during 
the period of follow up and excluded these from our estimates where relevant. 
Identification of Psychiatric Medication Usage
The PIS data allows medication to be identified by approved drug name and/or associated 
British National Formulary(BNF)(Joint Formulary Committee, 2012) paragraph code. 
Medication indication is not recorded in PIS. PIS records medication type, dose, dosage 
instructions and number of defined daily doses (DDDs) for each medication. DDDs are a 
measure for standardising drug doses(WHO, 2011). For a small part of the dataset (4.9%) the 
dosage instructions were missing, and these were imputed (as described in the Supplementary 
Materials). 
We defined antidepressants (drugs for depression) as any drug included in BNF Chapter 4.3, 
entitled “Antidepressant Drugs”.  Sel ctive Serotonin Reuptake Inhibitors (SSRIs) were 
identified via BNF Section 4.3.3, Tricyclic Antidepressants (TCAs) via Section 4.3.1 and, 
Selective Serotonin and Noradrenaline Reuptake Inhibitors(SNRIs) were identified from 
Section 4.3.4 (venlafaxine and duloxetine). We defined ,  and ‘other antidepressants’ as 
including Monoamine Oxidase Inhibitors (MAOIs), identified via Section 4.3.2, and  
(monoamine oxidase inhibitors, MAOIs) and the remaining drugs within Section 4.3.4 (other 
antidepressants). To comply with Neuroscience-based Nomenclature(Worley, 2017), a 
glossary of the mechanisms of action of each of the medications included in our study is 
provided in Table S5 of the Supplementary Material. 
We recorded antidepressant medication use as any dispensed prescription during the period 
analysed(which was the defined 5 year period 2012-2016 in some analyses and 1-5 years 
following individual GS:SFHS recruitment in others, as specified).  We also applied 
additional thresholds : in the majority of our analyses, and unless otherwise stated, we 
repeated our analyses excluding low dose (<75mg) amitriptyline prescriptions, as this 
medication and dosage is most commonly prescribed for non-psychiatric purposes (such as 
neuropathic pain, migraine and tension headache) and frequently for very short periods(Mars 
et al., 2017). With regard to antidepressant dosage, we produced estimates for antidepressants 
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8
of all dosages, and separate estimates for antidepressants prescriptions which met at least 
minimum BNF dose recommendations for MDD (for adult or older adults as appropriate). 
Prevalence and Incidence
For each one-year period, we calculated the number of patients receiving any antidepressant 
prescription. Annual prevalence was calculated as the number of living cohort members using 
at least one antidepressant prescription that year, as a proportion of the reference sample. We 
also calculated the period prevalence for 2012-16 and the period prevalence for 
antidepressant use in the five years following each individual’s enrolment in GS:SFHS.  
To calculate incidence, we defined antidepressant naïve individuals as those who (a) were not 
on any antidepressant at the time of enrolment to GS:SFHS, or the 6 months preceding, and  
(b) did not report antidepressant use on the medication self-report questionnaire included in 
GS:SFHS, and (c) did not have a history of MDD or bipolar disorder on the SCID (which 
would indicate likely, although not definite, previous antidepressant use) (d) did not have a 
previous diagnosis of affective or anxiety disorders in the Scottish Morbidity Record(SMR) 
prior to GS:SFHS recruitment. We calculated incidence on the basis of the number of new 
users from the antidepressant naïve group, divided by the number of cohort members without 
antidepressant use in the preceding year. 
Identification of Antidepressant Episodes and Adherence
We defined a drug treatment “episode” as consecutively dispensed prescriptions with a 
maximum interval between prescribing events of 90 days after the expected end date of the 
previous prescription, based on the dosage instructions(Gardarsdottir et al., 2010). We used 
90 days as the cut-off point as it is unusual in the UK to be given more than three months 
medication per prescribing event (for sensitivity analyses with alternative cut-off points see 
Table S6 in Supplementary Material). We did not include new episodes which began in the 
second half of 2016, as it was not possible to estimate their duration. We defined “long-term” 
antidepressant use as a consecutive antidepressant episode of at least 15 months (based on 
three months for acute treatment, nine months for continuation-phase treatment, and three 
months for discontinuation, following the approach of Keyloun (Keyloun et al., 2017)). 
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We calculated medication adherence using the Medication Possession Ratio (MPR) and 
Proportion of Days Covered (PDC) metrics(Keyloun et al., 2017). MPR is defined as the sum 
of the day’s supply for all dispensed medication in the episode divided by the number of days 
in the period, expressed as a percentage. PDC is defined as the number of days in a 
prescribing episode that are adequately “covered” by the preceding prescribing event, divided 
by the number of days in the episode, expressed as a percentage. Compared to MPR, PDC is 
generally regarded as a more conservative and preferred measure. Satisfactory adherence was 
defined as MPR or PDC >80% for the antidepressant episode(Keyloun et al., 2017).    
Statistical Analysis
All analyses were carried out using R version 3.2.3. Prevalence and incidence rates were 
expressed as percentages, together with 95% confidence intervals. These estimates were 
reweighted by age and sex to reflect the Scottish population, using the 2011 Scottish 
census(Scottish Government, 2011). Age-sex reweighting was performed using the direct 
standardisation method using the R package “epitools”. 
As GS:SFHS is a family based cohort, which could lead to biases due to the hierarchical 
structure of the data, we used a mixed model implementation of Cox regression (with inter-
relatedness controlled using pedigree as a random effect), using the R package “coxme”. We 
controlled for potential confounding related to the recruitment area from which each 
participant was enrolled using a categorical variable in the model. 
There was some (range 0.8-5.1%) missing data for some of the variables collected in 
Generation Scotland(see Supplementary Material including Table S2) and this missing data 
was imputed using the Multiple Imputation by Chained Equations method implemented in 
the R package “mice”. The final estimates were the result of pooling n=100 imputed datasets, 
using Rubin’s rules(van Buuren, 2012). Further details on the imputation, and the results of 
complete case analysis, are provided in the Supplementary Material. P values were corrected 
for multiple testing using the False Discovery Rate(FDR) method. 
Results 
Sample
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The basic demographics of the sample compared to the Scottish population are available in 
the Supplementary Material(Table S1). An antidepressant was prescribed at least once to 
3742 individuals (33.9(95%CI 33.0-34.8)%) of the 11,052 in our study between April 2009 
and December 2016. There was a 36.2% increase in the annual prevalence of antidepressant 
prescribing between 2010 (age-sex reweighted prevalence 12.7(95%CI 12.0-13.5)%) and 
2016 (17.3(16.5-18.3)%). During the seven year period 2010-16, 79,857 antidepressant 
prescriptions were dispensed (22 for every antidepressant user in GS:SFHS). 
Low dose amitriptyline prescriptions(<75mg) accounted for 18.3% of prescriptions and 943 
individuals (25%) were only prescribed low dose amitriptyline. Discounting low dose 
amitriptyline, there were 2624 antidepressant users with a mean of 1.8 antidepressant 
episodes (range 1-9, S.D. 1.1) during the period 2010-16. Although we had no data on 
specific indication, 84.2% of these episodes reached a dosage equivalent to at least the 
required BNF minimum for the treatment of Major Depressive Disorder. 
The most commonly prescribed class of antidepressants was Selective Serotonin Reuptake 
Inhibitors(SSRIs), accounting for 54% of prescriptions in 2010 and 52.7% in 2016 (65.6% 
and 64% respectively if low dose amitriptyline excluded). The proportion of Serotonin and 
Noradrenaline Reuptake Inhibitors(SNRIs) prescribed increased from 9.1% in 2010 to 10.9% 
in 2016, and the proportion of other antidepressants (such as mirtazapine) increased from 
6.7% to 8.3% during the same period. The proportion of Tricyclic Antidepressants(TCAs) 
was 27.8% in 2016, or 12.3% if low dose amitriptyline excluded. 
Period Prevalence 2012-16
The 5-year 2012-2016 age-sex reweighted period prevalence of antidepressant use was 
28.0(95%CI 26.9-29.1)% for the cohort. With low dose amitriptyline excluded, the 
prevalence was 20.8 (19.9-21.8)% (see Table 1). The five-year prevalence was considerably 
higher among females, 34.9(33.3-36.6)%, than males, 20.4(19.0-22.0)%. There was a 
bimodal distribution of antidepressant use by age, with 2012-16 period prevalence highest in 
the 45-54 age group for all antidepressants(33.3(31.3-35.3%)) and a second peak in the 75+ 
age group(33.3(28.8-38.8)%) (Figure 2). 
Prevalence of Antidepressant Prescribing in One to Five Years Follow-Up
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In the first year following each individual’s GS:SFHS enrolment, 11.2(95%CI 10.6-11.8)% 
of the cohort had at least one antidepressant prescription(excluding low dose amitriptyline, as 
does all analysis in this section), which increased to 20.8(20.0-21.6)% after five years.
Among those with history of recurrent MDD on recruitment, 52.4(48.5-56.2)% were 
prescribed at least one antidepressant within 1 year following GS recruitment and for bipolar 
disorder the proportion was 46.2(30.4-62.6)%. For those with no history of MDD on 
recruitment, 6.9(6.5-7.5)% were prescribed at least one antidepressant within one year – or 
2.5(2.2-2.9)% if those already on antidepressants at recruitment were excluded. 
Among those with a GHQ-28 Likert score of 24 or above at the time of GS:SFHS 
recruitment, 31.7(95% CI 29.4-34.1)% had at least one antidepressant prescription within 1 
year. Among the antidepressant naïve subgroup at the time of GS:SFHS recruitment, 6.6(5.1-
8.6)% of those with a Likert score of >=24 were prescribed antidepressants within 1 year and 
9.2(4.1-18.6)% of those scoring over three standard deviations above the mean on the GHQ 
depression subscale (subscale D) were prescribed an antidepressant within 1 year. 
Incidence of Antidepressant Prescribing 2012-16
The age-sex reweighted incidence of antidepressant prescribing was 2.4(2.1-2.7)% per year 
for all antidepressants and 1.6(1.4-1.9)% if low dose amitriptyline is excluded. Incidence was 
greater in females 2.7(2.4-3.2)% than males 2.0(1.6-2.5)%. 
77.1% of incident antidepressant users were commenced on an SSRI, with 11.9% on a TCA 
(low dose amitriptyline excluded), 4.0% on a serotonin and noradrenaline reuptake 
inhibitor(SNRI) and 7.0% on other antidepressants(especially mirtazapine). The most 
common individual medication for new users was citalopram (39.9%), followed by fluoxetine 
(21.6%) and sertraline (14.2%). Less than 1% were commenced on paroxetine and none on 
reboxetine or MAOIs. The most common tricyclic antidepressant for new users was 
nortriptyline (3.9%) followed by higher dose amitriptyline(3.0%). 
Antidepressant Episodes
In the five years period 2012-16, 2385 individuals used antidepressants and we defined 3595 
antidepressant episodes(low dose amitriptyline excluded). Some 86.6% (n=3112) of episodes 
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reached at least minimum dose required for treatment of MDD (although actual indication 
was not available). We allowed antidepressant switching or combination during episodes, 
with the majority of episodes(79.3%) having just one antidepressant, 13.6% having two and 
7.1% having three or more(range 3-6). 
Over half (57.6%) of antidepressant episodes were of 9 months or greater and 44.8% met our 
15-month criteria for long term use, with the majority of antidepressant users (57.7%) having 
a least one episode of long term duration. Nevertheless, approximately one tenth (10.6%) of 
episodes were of less than 30 days duration and a further 12.6% were of 31-90 days, meaning 
that approximately one quarter of episodes were less than three months duration. 
Adherence
For the 3595 antidepressant episodes between 2012-16(n=2385 individuals), the mean 
Medication Possession Ratio(MPR) per antidepressant episode was 96.0% (range 11-412) 
and the mean Proportion of Days Covered(PDC) was 84.9% (range 11-100). Using PDC >= 
80% as defining adherence, 69.0% of antidepressant episodes were adherent, when using 90 
days as the cut-off point between antidepressant episodes (for sensitivity analysis see Table 
S6 in Supplementary Materials). Mean PDC was similar across medication classes (SSRI 
84.5%, TCA 84.3%, SNRI 83.2%, MAOI 77.3%, other 83.9%, see Table S6 in 
Supplementary Materials). 
Polypharmacy 
Other medications that were co-prescribed with antidepressants during an antidepressant 
episode were determined, with simultaneous use on at least three occasions being classed as 
“regular” use.  Anxiolytics (medicines for anxiety) were co-prescribed to 34.1% of 
antidepressant users (16.4% regularly), including benzodiazepines 23.6% (10.7% regularly) 
and “Z-drugs”(the benzodiazepine-receptor agonists zopiclone, zolpidem and zaleplon) 
18.9% (7.6% regularly). Pregabalin or gabapentin (alpha-2 delta calcium channel blockers 
often used to treat anxiety and neuropathic pain as well as epilepsy) were co-prescribed to 
12.8% users (8.9% regularly). Antipsychotics (medicines to treat psychosis) were co-
prescribed to 6.8% antidepressant users (5.1% regularly). Lithium compounds or sodium 
valproate, which are also used to treat mood disorders, were co-prescribed to 1.6% (1.4% 
regularly). Opiate-based analgesic (pain relieving) medications were co-prescribed to 22% of 
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antidepressant users (13.3% regularly), compared to a general five-year prevalence of 15.6% 
(Figure 3).  Opioid use was also higher in those with a history of bipolar disorder 
(33.3%,regular 18.5%) and recurrent MDD (27.8%, regular 17.3%) on GS:SFHS recruitment, 
compared to those with no affective disorder history (20.5%, regular 12.3%).  
Use of psychiatric services
Using record linkage to hospital data, 10.0(8.9-11.2)% of antidepressant users in the five 
years following GS:SFHS enrolment, who were prescribed at least the minimum BNF 
recommended dosage for MDD,  had a psychiatric outpatient appointment during at least one 
of their antidepressant treatment episodes. Some 1.8(1.4-2.5)% of antidepressant users were 
admitted to psychiatric hospital during at least one episode of antidepressant treatment. 
Predictors of antidepressant use - time to event analysis 
We performed time-to-antidepressant-use Cox regression analysis for the five years 
following individual GS:SFHS enrolment, excluding those individuals already on 
antidepressants (Figure 4 and Table 2). Female gender was predictive of commencing 
antidepressants in the multivariable model (Hazard Ratio(HR)=1.74, 95% CI 1.53-1.98, 
pFDR<0.0001). Lower SIMD deprivation status was associated with antidepressant use in 
univariate analysis (and in complete case analysis, see Supplementary Table S3) but was not 
significant in the multivariable model. Neuroticism (HR 1.12,1.09-1.14 per unit, 
pFDR<0.0001), previous history of unemployment(HR=1.24, 1.06-1.45, pFDR=0.02)  and 
smoking status (current smokers HR 1.57(1.34-1.84, pFDR <0.0001) were also positively 
associated with antidepressant use, whereas cognitive function (g) scores were negatively 
associated (HR 0.89, 0.85-0.93, pFDR 0.001). Multiple physical comorbidities (3+) were 
positively associated with antidepressant use (HR 1.85,1.33-2.57, pFDR 0.002). The most 
predictive factor for antidepressant use was previous history of affective disorder on 
GS:SFHS recruitment, with history of a single episode of MDD having a hazard ratio of 2.22 
(1.85-2.67, pFDR<0.0001). 
Discussion 
Summary of Main Results
In this study, we demonstrate an increase in antidepressant usage in this UK cohort, with an 
estimated 17.3% of the adult population using antidepressants in 2016, an increase of nearly 
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one third(36.2%) on 2010(see Supplementary Table S4). We have found that, even if low 
dose amitriptyline use is discounted, one fifth of our sample (20.8%) has been prescribed an 
antidepressant at least once between 2012-16. The prescribing of antidepressants continues to 
be dominated by the SSRI class, but we observed a rise in the proportion of SNRIs, and other 
antidepressants such as mirtazapine, prescribed. This is an interesting trend and may be 
further stimulated by future revisions of clinical guidance, which may recategorize 
mirtazapine as a first-line treatment in psychiatric disorders such as major depression, leading 
to further increases in prevalence of use and interest in the efficacy and safety profile of 
mirtazapine and other non-SSRI antidepressants(Coupland et al., 2015; Cipriani et al., 2018). 
Our findings accord with recent UK data which has found that antidepressant prescribing is 
the highest ever at 64.7m prescriptions for England in 2016(NHS Digital, 2017). However, in 
this study we also found a reweighted incidence for new antidepressant users of just 2.4%, 
and a duration for antidepressant episodes of in excess of 15 months in nearly half of 
episodes identified. This supports the hypothesis of increased longer-term use by regular 
antidepressant users driving much of the increased prevalence of antidepressants we report.  
Our study also found that adherence to antidepressants was relatively high, meeting the more 
conservative PDC threshold adherence of 80% in 69.0% of cases. 
We found that history of affective disorder, multiple physical comorbidities, and being 
female, were the most predictive of antidepressant use. We also report an interesting 
association between neuroticism and antidepressant use, with considerably greater incident 
antidepressant use in the upper tertile of EPQ-SF neuroticism scores(Figure 4). Neuroticism 
is a personality trait with significant clinical overlap with psychiatric disorder(Smith et al., 
2016), which is relatively straightforward to measure prospectively, and our results suggest 
that it could be a useful predictor of future antidepressant usage. A recent study in older 
adults (Steffens et al., 2018)has found that neuroticism may be also associated with lower 
remission rates of antidepressant-treated depression. We also found that cognitive function 
had an inverse association with antidepressant use, in line with previous research indicating 
an association between cognitive impairment and MDD(Marazziti et al., 2010). 
With this study methodology we cannot judge definitely whether the increasing 
antidepressant prevalence we found is appropriate to clinical indication.  The prevalence of 
prescribing we report should be seen in the context of not only the prevalence of MDD, but 
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the prevalence of anxiety disorders, eating disorders, sexual disorders, sleep disorders and 
other indications for antidepressant medication. Nevertheless, it has also been argued that 
current rates of antidepressant treatment may still not identify all those most likely to benefit 
(Kendrick et al., 2005). The National Health and Nutrition Examination Surveys 2005-
08(Pratt et al., 2011) found that only one third of those with severe depressive symptoms 
were on antidepressant therapy, and less than half of those taking multiple antidepressants 
had seen a mental health professional in the past year. In our study, we found that, among 
those antidepressant naïve individuals with the highest psychiatric ‘caseness’ according to 
GHQ scores in Generation Scotland, just 6.6% were prescribed an antidepressant within one 
year of follow-up, and less than 10% of those with the highest severe depression caseness 
(three standard deviations on the GHQ-28 D subscale) were prescribed an antidepressant 
within one year.  This might indicate potential unmet clinical need for antidepressants, 
although such a conclusion should be approached with caution as GHQ is a measure of 
psychiatric distress at one timepoint, and higher GHQ scores do not necessarily indicate 
requirement for antidepressants. 
It has also been previously argued that antidepressants are insufficiently reviewed by 
clinicians, leading to unnecessarily long treatment durations(Bosman et al., 2016; Johnson et 
al., 2012). The European Study of the Epid miology of Mental Disorders (ESEMed) 
demonstrated that 63.5% of those with mood disorders had not consulted health services in 
the previous 12 months(Alonso J, 2004), with similar findings in the US National 
Comorbidity Survey Replication(Wang et al., 2005).  We found that only a small minority of 
antidepressant users are being reviewed in outpatient psychiatry, suggesting that the majority 
of antidepressant monitoring takes place in primary care. The high prevalence of 
antidepressant use we report suggests that there may be scope for increasing the rate of 
medication reviews for long-term antidepressant users in primary (and secondary) care, with 
consideration of managed discontinuation of treatment. This can help manage the risks 
associated with prolonged antidepressant exposure when a sustained recovery from illness 
has been achieved. 
Among medications frequently co-prescribed with antidepressants, the most common 
psychiatric class was anxiolytics, especially benzodiazepines and “Z-drugs”. We found that 
the co-prescribing of analgesic and opiate medication was appreciably higher in 
antidepressant users, especially those with a history of recurrent depression and bipolar 
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disorder. An association between depression and pain has been previously 
described(McIntosh et al., 2016) and could be related to altered pain sensitivity in depressed 
states and comorbidity of depression with painful conditions.
Comparison With Previous Studies 
A previous prescribing database study of the Tayside population of Scotland 
(n=325,000)(Lockhart and Guthrie, 2011) found an increase in prevalence from 8.0% in 
1995/96 to 13.4% in 2006/07. The standardised rate for 2006-07 antidepressants was 13.1% 
(SSRIs 7.9%, TCAs 5.2%, other antidepressants 1.9%) compared to the reweighted 2016 
rates of 17.3% (10.5%, 5.8%, 3.2%) found in our study. Analysis of the UK Clinical Practice 
Research Datalink (CPRD, N=1,524,201) found that 23% of individuals were prescribed at 
least one antidepressant between 1995 and 2001(Mars et al., 2017). 
Results from the US National Health and Nutrition Examination Survey (NHANES) found a 
2009-10 annual prevalence of 10.4%(Mojtabai and Olfson, 2014), with 67.4% reporting use 
for 24 months or longer, and 17.1% for <6 months. Incidence was estimated at 2.55% (per 
100 individuals per year) in comparison with our estimated incidence of 2.4%. In this US 
study, 32.5% of antidepressant users had visited a mental health professional in the previous 
year, compared with 10.0% in our UK-based study. 
A prescription database study in British Columbia conducted in 2004(Raymond et al., 2007) 
found a prevalence of 7.2% and found that lower socioeconomic groupings and lowest 
income groupings had higher prevalences of antidepressant use. In our time-to-event analysis 
we found the lowest SIMD quintiles were associated with antidepressant use in univariate 
analysis but not in the multivariable model.  
A recent study of routine general practice care data in a cohort based in Amsterdam 
(n=156,620) found 43.7% of antidepressant users were long-term users(Huijbregts et al., 
2017), which is similar to our own finding of 44.8%. 
Strengths and Limitations
This study benefitted from the relatively large population-based GS:SFHS cohort and the 
availability of structured clinical interview data alongside quantitative measures of non-
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specific psychiatric morbidity and numerous demographic, socio-economic and 
psychological variables. The national prescribing and morbidity data to which it was linked 
was of high fidelity (with a capture rate in excess of 95%) and, being nationally based, 
reduced the chance of individuals being lost to follow up during the study period due to, for 
example, moving their GP practice. We were also able to record the date of dispensing as 
well as prescribing, and whether the medication was collected. By applying a longitudinal 
retrospective design rather than a cross-sectional approach, this study increased the potential 
for accurate measurement of the pharmaco-epidemiological variables. 
However, by using a cohort study as its basis, this analysis is also susceptible to selection and 
confounding biases. Another significant limitation is the lack of details of the indication of 
medication use in the PIS prescribing data(as with many other prescribing databases based on 
routinely collected administrative data). In GS:SFHS, previous history of affective disorder 
was collected via screening using the SCID, but we were not able to determine ongoing and 
subsequent psychiatric diagnoses in the period studied following GS:SFHS recruitment. It is 
likely that a proportion of those individuals with no previous history of affective disorder 
were subsequently diagnosed with such, or that other psychiatric disorders such as anxiety 
disorders were the indication for later antidepressant treatment. GS:SFHS did not provide 
data on baseline history of anxiety disorders to complement the SCID-derived history of 
affective disorders. We were also not able to determine the extent to which severity of 
psychiatric symptoms or level of functional impairment determines antidepressant usage. 
Prescribing data is also an imperfect proxy for medication use, given that the medication may 
not be taken (primary noncompliance) or may not be used as directed (secondary 
noncompliance). Noncompliance to antidepressant medication has been previously estimated 
at 50%(Haynes et al., 2008).  The PIS prescribing data only covered prescriptions issued in 
the community, and therefore may underestimate true prevalence and treatment duration, 
although it would be expected that most antidepressant users commenced in hospital would 
continue medication in the community. A further limitation of our study being based on 
routinely collected administrative prescribing data is that it is also not possible to determine 
the extent to which the antidepressant prescribing we recorded was appropriate to clinical 
need or consistent with treatment guidelines.
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Although we attempted to apply stringent criteria for incident use of antidepressants - using 
prescription data, linked morbidity data, self-report and objectively measured history of 
affective disorder to screen antidepressant naïve cohort members - we may still have falsely 
identified some previous antidepressant users as incident cases, particularly as we did not 
have data preceding April 2009. 
Our Cox regression analysis of predictors of antidepressant use within 5 years was 
necessarily restricted by the variables available to us in GS:SFHS. We were able to derive 
effect sizes for numerous variables previously associated with antidepressant use, such as 
history of affective disorder, medical comorbidities and female gender. However, due to the 
limited diagnostic information available in GS:SFHS we were not able to quantify the 
association between non-affective psychiatric disorders such as anxiety disorders (which are 
likely to be significantly predictive) and antidepressant use. The conclusions of our time-to-
event analysis need to be placed in the context of the variables available in our model. 
The cohort was also for adults only, thereby not including antidepressant use among the 
under 18s, and the overall population prevalence and incidence would be expected to be 
lower than our figures since children are prescribed antidepressants less frequently. 
Future Directions and Clinical Implications 
We found that antidepressant prevalence was higher than previously reported for the UK, but 
that incidence remains relatively stable. This suggests that increased antidepressant 
prevalence is driven by longer treatment durations and good levels of adherence, and 
previous users returning to medication for a wider range of indications, rather than an 
upsurge in incident cases. Our study also demonstrates the utility of record-linking 
administrative health data to population-based cohorts to provide enhanced pharmaco-
epidemiological estimates of prevalence, incidence and adherence. We also found significant 
relationships between neuroticism and cognitive function for antidepressant use, even when 
affective disorder was controlled for. These tests are relatively easy to administer and could 
provide useful to clinicians in constructing predictive models of clinical risk. 
More research is required to investigate the clinical appropriateness of antidepressant 
prescribing. Our research suggests that the vast majority of antidepressant prescribing and 
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medication review takes place in the primary care setting in the UK.  Primary care will 
necessarily therefore remain the focal point for future efforts to improve antidepressant 
prescribing practices, monitoring of adherence and adverse effects, and managed 
discontinuation of treatment when clinically appropriate. 
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Pharmaco-epidemiology of Antidepressant Exposure in a UK Cohort Record-Linkage 
Study
Hafferty JD, Wigmore EM, Howard DM, Adams MJ, Clarke T-K, Campbell AI, MacIntyre DJ, 
Nicodemus KK, Lawrie SM, Porteous DJ, McIntosh AM
Table 1 : Prevalence of Antidepressant Medications, by Class, 2012-2016
 
All 
antidepressant SSRI TCA
Other 
antidepressants
Antidepressants 
excluding low 
dose amitriptyline
2012-16 n 2012-16 n 2012-16 n 2012-16 n 2012-16 n
Crude Rate 29.5(28.6-30.4) 3167 17.4(16.7-18.2) 1883 15.0(14.3-15.7) 1619 5.8(5.4-6.3) 630 21.9(21.1-22.7) 2366
Reweighted Rate 28.0(26.9-29.1) 16.5(15.7-17.4) 14.1(13.4-15.0) 5.6(5.1-6.2) 20.8(19.9-21.8)
Sex -Male (crude) 20.4(19.2-21.7) 900 11.1(10.2-12.1) 489 10.0(9.1-11.0) 440 4.4(3.8-5.1) 195 14.7(13.7-15.8) 647
                    (RW) 20.4(19.0-22.0) 11.1(10.1-12.3) 9.9(8.7-11.1) 4.4(3.8-5.2) 14.7(13.5-16.1)
Sex – Female       
                    (crude) 35.4(34.3-36.6) 2267 21.8(20.8-22.8) 1394 18.4(17.4-19.4) 1179 6.8(6.2-7.5) 435 26.9(25.8-28.0) 1719
                     (RW)
34.9 (33.3-
36.6) 21.4(20.2-22.7) 18.1(16.9-19.3) 6.7(6.0-7.5) 26.4(25.0-27.9)
Age - 18-24 22.6(19.8-25.7) 181 18.4(15.8-21.3) 147 6.6(5.0-8.6) 53 4.0(2.8-5.7) 32 19.5(16.8-22.4) 156
25-34 23.0(20.9-25.3) 335 17.5(15.6-19.5) 255 8.5(7.1-10.0) 123 4.7(3.7-6.0) 71 19.5(17.5-21.7) 284
35-44 32.9(30.7-35.1) 601 22.5(20.6-24.5) 411 14.1(12.5-15.8) 257 7.3(6.2-8.7) 134 26.6(24.6-28.7) 487
45-54 33.3(31.3-35.3) 739 20.6(19.0-22.4) 458 16.8(15.3-18.4) 373 6.1(5.1-7.2) 136 25.2(23.4-27.1) 560
55-64 29.1(27.4-30.7) 858 14.9(13.6-16.3) 440 17.0(15.7-18.4) 503 6.0(5.2-6.9) 177 20.6(19.1-22.1) 607
65-74 28.3(25.8-30.9) 346 10.6(9.0-12.5) 130 19.5(17.4-21.9) 239 4.6(3.5-5.9) 57 16.4(14.4-18.7) 201
75+ 33.3(28.3-38.8) 107 13.1(9.7-17.4) 42 22.1(17.8-27.1) 71 7.2(4.7-10.7) 23 22.1(17.8-27.1) 71
Abbreviations : RW=age-sex reweighted.  SSRI=Selective Serotonin Reuptake Inhibitors. TCA=Tricyclic Antidepressants. n = total number within grouping with prescription 
records of at least one antidepressant usage. 
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Pharmaco-epidemiology of Antidepressant Exposure in a UK Cohort Record-Linkage 
Study
Hafferty JD, Wigmore EM, Howard DM, Adams MJ, Clarke T-K, Campbell AI, MacIntyre DJ, 
Nicodemus KK, Lawrie SM, Porteous DJ, McIntosh AM
Table 2 : Cox Regression of Time-To-Antidepressant-Use in GS:SFHS (Excluding those 
Already Using Antidepressants At Time Of Recruitment), 
N=9953 of whom n=1347 went on to use antidepressants within 5 years
Univariate 
Hazard Ratio p
Multivariable
Hazard Ratio p(FDR) Sig
Intercept
Sex – male Ref Ref Ref Ref
       – female 1.94(1.72-2.19) <0.0001 1.74(1.53-1.98) <0.0001 ***
Age :18-24 Ref Ref Ref Ref Ref
        :25-34 0.81(0.64-1.03) 0.16 0.79(0.62-1.01) 0.119  
        : 35-44 1.03(0.83-1.28) 0.92 0.95(0.75-1.21) 0.787  
        : 45-54 0.99(0.80-1.22) 0.92 1.00(0.79-1.26) 0.993  
        : 55-64 0.72(0.58-0.89) 0.007 0.72(0.57-0.92) 0.021 * 
        :65-74 0.49(0.37-0.64) <0.0001 0.48(0.35-0.64) <0.0001 ***
        :75+ 0.93(0.67-1.29) 0.92 0.74(0.52-1.07) 0.193  
No MDD on Screening Ref Ref Ref Ref Ref
MDD - Single Episode 3.17(2.69-3.76) <0.0001 2.22(1.85-2.67) <0.0001 ***
MDD - Recurrent 4.33(3.54-5.30) <0.0001 2.10(1.68-2.62) <0.0001 ***
MDD - Bipolar 4.84(2.38-9.85) <0.0001 2.11(0.99-4.47) 0.109  
Never Smoked Ref Ref Ref Ref Ref
Currently Smoke 2.05(1.78-2.37) <0.0001 1.57(1.34-1.84) <0.0001 ***
Ex-Smoker 1.30(1.14-1.48) <0.0001 1.33(1.15-1.53) 0.001 *
Neuroticism 1.20(1.18-1.22) <0.0001 1.12(1.09-1.14) <0.0001 ***
SPQ 1.11(1.09-1.12) <0.0001 1.03(1.01-1.05) 0.003 *
Cognitive function (g) 0.85(0.81-0.89) <0.0001 0.89(0.85-0.93) <0.0001 ***
No physical health complaints Ref Ref Ref Ref Ref
1-2 physical health complaints 1.22(1.08-1.38) <0.0001 1.27(1.11-1.44) 0.003 *
3+ physical health complaints 1.79(1.34-2.41) <0.0001 1.85(1.33-2.57) 0.002 *
Unemployment history 1.24(1.06-1.45) 0.021 *
SIMD – Most Deprived quintile 2.03(1.70-2.42) <0.0001 1.23(1.01-1.49) 0.086 .
SIMD – 2nd quintile 1.47(1.23-1.76) <0.001 1.07(0.88-1.29) 0.64
SIMD – 3rd quintile 1.27(1.06-1.52) 0.013 1.06(0.88-1.28) 0.64
SIMD – 4th quintile 1.02(0.87-1.21) 0.79 0.93(0.78-1.10) 0.54
SIMD – Least Deprived quintile Ref Ref Ref Ref Ref
N.B. The following covariates were in the model but not shown as not significant in multivariable analysis: Location of 
GS:SFHS enrolment(not significant in univariate or multivariable analyses), self-reported alcohol use, body mass index (bmi). 
Abbreviations:  Sig=significance level *p<0.05, **p=<0.001, ***p<0.0001  Ref=reference level g = cognitive function score. 
GHQ = General Health Questionnaire. MDD = Major Depressive Disorder. SIMD = Scottish Index of Multiple Deprivation.   
SPQ = Schizotypal Personality Questionnaire. 
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Figure 1 : Derivation of Study Population from Generation Scotland cohort
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Hafferty JD, Wigmore EM, Howard DM, Adams MJ, Clarke T-K, Campbell AI, MacIntyre DJ, 
Nicodemus KK, Lawrie SM, Porteous DJ, McIntosh AM
Figure 2 : 2016 Age and sex specific period prevalence of antidepressant for all 
antidepressant types and indications 
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Pharmaco-epidemiology of Antidepressant Exposure in a UK Cohort Record-Linkage 
Study
Hafferty JD, Wigmore EM, Howard DM, Adams MJ, Clarke T-K, Campbell AI, MacIntyre DJ, 
Nicodemus KK, Lawrie SM, Porteous DJ, McIntosh AM
Figure 3 : Age-Sex Reweighted Prevalence of Antidepressants And Other Medications In 
GS:SFHS
 
Abbreviations : LDA= low dose amitriptyline. 
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1
Pharmaco-epidemiology of Antidepressant Exposure in a UK Cohort Record-Linkage 
Study
Hafferty JD, Wigmore EM, Howard DM, Adams MJ, Clarke T-K, Campbell AI, MacIntyre DJ, 
Nicodemus KK, Lawrie SM, Porteous DJ, McIntosh AM
Figure 4 : Kaplan-Meier Time To Event Curves For Incident Antidepressant Prescriptions 
In 5 Years Following Recruitment To GS:SFHS
History of affective disorder is defined as previous history of single or recurrent episode MDD or bipolar disorder on the SCID interview. ‘High’ 
neuroticism is defined as a neuroticism score occurring in the upper tertile of Eysenck Personality Questionnaire-Short Form neuroticism scores, 
and ‘low’ is defined as occurring in the lower tertile. Abbreviations :   “F” = Female. “M”=Male. 
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Pharmaco-epidemiology of Antidepressant Exposure in a UK Cohort Record-Linkage 
Study
Hafferty JD, Wigmore EM, Howard DM, Adams MJ, Clarke T-K, Campbell AI, MacIntyre DJ, 
Nicodemus KK, Lawrie SM, Porteous DJ, McIntosh AM
Supplementary Material
Generation Scotland : Scottish Family Health Study : Cohort Information
For full cohort profile, please refer to Smith et al. “Cohort Profile: Generation Scotland: Scottish 
Family Health Study (GS:SFHS). The study, its participants and their potential for genetic research 
on health and illness” International Journal of Epidemiology 2013: 42:689-700
Generation Scotland:Scottish Family Health Study(GS:SFHS) is a population- and family-based 
epidemiology study, with socio-demographic, clinical and genetic phenotyping. Potential 
participants were identified at random from lists provided by collaborating general medical 
practices across Scotland. In the UK, 96% of the population is registered with a GP and thus this 
recruitment method was favoured for recruiting a population-based sample. Invitations to 
participate were blinded to health status.  
Potential participants were invited to the study and also to identify at least one first-degree relative 
(aged 18+) who would also participate. Nominated first-degree relatives could be from any 
location. The first recruitment phase (2006-10) involved potential participants aged 33-65 years 
and at least one nominated first-degree relative (aged 18+) from GP practices in Glasgow and 
Tayside areas of Scotland. In the second phase (2010-2011) the study was extended to include 
Aryshire, Arran and Northeastern Scotland, and the age of potential participants was broadened to 
18-65 years (invited relatives remaining aged 18+). 
In total, 126000 potential participants were invited and 12.3% volunteered and met study criteria. 
Not all participants were recruited, for logistical reasons or due to failure to recruit additional 
family members, leaving a total recruitment of 6665 (5.3% overall response rate). An additional 
1288 individuals volunteered directly (age >18 years and at least one additional relative who 
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agreed to participate). A further 16007 family members associated with these invited participants 
and volunteers were also recruited, giving a total of 23960. 
A total of 21474 individuals attended Generation Scotland research clinics in Glasgow, Dundee, 
Perth, Aberdeen or Kilmarnock. Prior to their appointment they completed a pre-clinic 
questionnaire. At the clinic appointment, a variety of measures were taken by trained clinic staff. 
This included screening for emotional and psychiatric problems using the structured clinical 
interview for DSM-IV disorders (SCID)  (99.6% of cohort completed), mood sections of the SCID 
in the case of positive screening (18.8% completed), Eysenck personality questionnaire (99.4% 
completed), digit symbol test(98.8% completed), verbal fluency (98.7% completed), Mill Hill 
vocabulary scale (98.2% completed) and Wechsler memory test (99.3% completed). In total, 
20,198 individuals completed all components of the phenotyping, including a two-hour face-to-
face interview and sociodemographic and clinical questionnaires.  
Written informed consent was also obtained for 98% of GS:SFHS for data linkage to routinely 
collected health records and only those individuals who provided consent were used in this study.
Subset of Generation Scotland Used In This Study
Recruitment to Generation Scotland began in February 2006 and ended in March 2011. However, 
the Prescribing Information System (PIS) data is only available from April 2009 onwards (data 
prior to that is not considered by Information Services Division Scotland to be complete and 
comprehensive enough for research purposes). We therefore restricted our analysis to those 
individuals in GS:SFHS recruited from September 2009 to March 2011 (N=11052, 6518 females 
and 4534 males). This ensured that all individuals had at least five years’ worth of prescribing data 
following their enrolment in GS:SFHS, and also at least six months of prescribing data prior to 
their enrolment, with which to ascertain their pre-enrolment medication usage. Of these, 96.5% 
had medication records available in the prescribing data (the remainder were presumably not using 
prescribed medication), which compared with 95.6% for the whole GS:SFHS cohort (see Figure 
1). 
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Table S1 :  Demographics of Individuals Used In Current Study Compared to Entire Generation Scotland 
Cohort And To The Scottish Adult Population 
Individuals in the current study  
N(%)
GS:SFHS
N(%)
Significance (p) of 
difference in proportion 
between study sample 
and GS:SFHS
Effect size (Cohen d/h)
Scottish 18+ 
population 
N (%)
(N=11052)
(N=20759) †
(N=4.3M)
Female 6518  (59.0%) 12246 (59.0%) p=0.98 2.24M (52.1%)
Age 18-24 (Age in 2012) 801 (7.3%) 1194  (5.8%) p=1.6x10-07h = 0.06 501152  (11.7%)
Age 25-34 1460  (13.2%) 2810 (13.5%) p=0.42 691908 (16.1%)
Age 35-44 1837  (16.6%) 3416  (16.5%) p=0.70 688418  (16%)
Age 45-54 2246  (20.3%) 4422  (21.3%) p=0.04    h=0.02 800265  (18.6%)
Age 55-64 3022  (27.3%) 5447  (26.2%) p=0.03   h=0.03 663701  (15.5%)
Age 65-74 1295  (11.7%) 2649  (12.8%) p=0.007  h=0.03 522236  (12.2%)
Age 75+
Affective Disorder History
391  (3.5%) 821  (4.0%) p=0.06 424626  (9.9%)
No MDD on screening 9624  (87.1%) 17998  (86.7%) p=0.34
SCID Single episode MDD 729  (6.6%) 1360  (6.6%) p=0.88
SCID Recurrent MDD 660  (6.0%) 1327  (6.4%) p=0.14
SCID Bipolar disorder
Recruitment Location
Aberdeen
Alyth
Ayrshire
Glasgow (BHF)
Dundee
Perth
Glasgow (Tennents) 
Dundee/Tayside
Deprivation Index
39  (0.4%)
1133 (10.3%)
0 (0%)
70 (0.6%)
2235 (20.2%)
3888 (35.2%)
1106 10.1%)
2620 (23.7%)
0 (0%)
74  (0.4%)
1133 (5.5%)
14 (0.06%)
70 (0.3%)
4821 (23.2%)
6926 (33.4%)
3429 (16.5%)
4214 (20.3%)
152 (0.7%)
p=0.96
p=<2.2x10-16 h=0.18
p=0.0002 h=0.04
p=8.5x10-10 h=0.07
p=0.001 h=0.04
p=<2.2x10-16 h=0.19
p=1.9x10-12 h=0.08
SIMD 1 - Most Deprived 1325(  12.6%)* 2597  (13.3%)* p=0.11  
SIMD 2nd quintile 1576  (15.0%)* 2761  (14.1%)* p=0.04  h=0.03
SIMD 3rd quintile 1693  (16.1%)* 3137  (16.0%)* p=0.84
SIMD 4th quintile 2604  (24.8%)* 5009  (25.6%)* p=0.12
SIMD 5 - Least Deprived
Smoking History
Never Smoked
Currently Smoke
Ex- Smoker 
Other Variables
GHQ (Likert)
EPQ Neuroticism 
Mill-Hill Vocabulary Test
3293  (31.4%)*
5636 (52.8%)*
1834 (17.2%)*
3198 (30.0%)*
15.8 (8.8)*
3.7 (3.1)*
30 (4.7) *
6043  (30.9%)*
10604(52.8%)*
3565 (17.7%)*
5918 (29.5%)*
16.0 (8.7)*
3.8 (3.1)*
30 (4.8)*
p=0.40
p=0.95
p=0.22
p=0.34
p=0.09
p=0.0003 d=0.04
p=0.55
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Wechsler Digit Symbol 
Substitution Task 
Verbal Fluency Test 
Body mass index 
72.0 (17.2)*
39.8 (11.7)*
26.8 (5.2)*
72.1 (17.3)*
39.7 (11.7)*
26.7 (5.3) *
p=0.02 d=0.03
p=0.27
p=0.05
Abbreviations: MDD = Major Depressive Disorder. SCID = Structured Clinical Interview for DSM-IV Disorders.          
SIMD = Scottish Index of Multiple Deprivation. GHQ = General Health Questionnaire. EPQ = Eysenck Personality 
Questionnaire. 
* Variable contained missing data which was imputed (see below)
An additional table with the other covariates used in the study is provided in Supplementary Materials
† Total GS:SFHS cohort 21474 but number who had consented to data linkage and where data linkage was possible 
was 20759
Imputation method for missing drug dosage data
There were 8048 records in the antidepressant data with missing prescription instructions (out of 
134290 records in total, or 6.0% missing data).  A five-step imputation strategy was employed for 
these missing records. 
(1) If a missing data prescribing record could be matched to one with the same user (unique 
ID), the same antidepressant medication, at the same dose, and the same dispensed 
quantity, then these prescribing instructions were used to impute for that individual. This 
reduced the missing data from 8048 records to 814 records. 
(2) If a prescribing record has the same user (unique ID), the same antidepressant, and the 
same strength as another prescription for the same users, then these prescribing instructions 
were used. This step did not reduce the count (did not improve upon the step above). 
(3) If a missing data prescribing record could be matched to one with the same user (unique 
ID) and the same antidepressant, then these prescribing instructions were used to impute. 
This reduced missing data from 814 to 553 records. 
(4) For the remaining 553 records (0.4% of the total dataset) the median dosage instructions 
for that specific antidepressant in the cohort were used. 
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Missing Data and Imputation of Generation Scotland phenotypic variables 
As shown in Table 2, there was some missing data in the phenotypic variables used in the analyses 
of this study. The amount of missing data was <5% for every variable apart from SIMD quintile 
(5.1%) with the proportion of individuals with missing data in at least one field being 12.6%. 
Imputation of these variables was performed using Multiple Imputation by Chained Equations in 
the R package “mice”. An assumption of multiple imputation is that the missing data is not Not 
Missing At Random(NMAR) and can credibly be defined as Missing At Random(MAR) or 
Missing Completely At Random(MCAR). 
As shown in Table 2, when stratified against the affective disorder status of GS:SFHS participants, 
there are no significant differences in the total missingness between those with a history of 
affective disorder and those without. We imputed the missing data on the basis of the hypothesis 
that the missingness was MAR type. 
Complete case analysis (N=6855) for the time-to-event Cox regression is shown below in Table 
S3. 
Table S2 : Missing Data in GS Variables
Variable name Missing records 
(N=11052)
% missing data 
(which was 
imputed)
% missingness in 
individuals with no 
history of affective 
disorder
% missingness in 
individuals with history 
of affective disorder
(p= p value of two 
sample test for equality 
of proportions)
Sex 0 -
Age 0 -
SCID affective 
disorder status
0 -
SIMD Quintile 561 5.1% 5.0% 5.7%(p=0.3)
BMI 91 0.8% 0.8% 0.8% (p=0.9)
SPQ 261 2.4% 2.3% 2.7%(p=0.05)
Neuroticism 254 2.3% 2.4% 1.9%(=0.3)
Smoking 384 3.5% 3.5% 3.4%(p=0.9)
Alcohol 535 4.8% 4.7% 5.5% (p=0.2)
Physical Health 254 2.3% 2.3% 2.6%(p=0.05)
Appointment 
location
0 -
Cognitive function 
(g)
203 1.8% 1.9% 0.9%(p=0.007)
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Individuals with 
missing data in at 
least one field
1397 12.6% 12.7% 12.5%(p=0.9)
Table S3 : Complete Case Analysis Cox Regression of Time to Antidepressant Use in Generation Scotland Cohort 
(Excluding those Already Using Antidepressants At Time Of Recruitment), n=6855
Multivariable
Hazard Ratio p(FDR) Sig
Intercept
SexM Ref Ref
SexF 1.83(1.59-2.10) <0.001 ***
Age_18-24 Ref Ref Ref
Age_25-34 0.77(0.59-1.01) 0.126  
Age_35-44 1.00(0.78-1.28) 1.00  
Age_45-54 1.02(0.80-1.31) 0.919  
Age_55-64 0.77(0.60-0.99) 0.093 . 
Age_65-74 0.48(0.35-0.66) <0.0001 ***
Age_75+ 0.77(0.51-1.15) 0.30  
No MDD on Screening Ref Ref Ref
MDD - Single Episode 2.13(1.76-2.58) <0.001 ***
MDD - Recurrent 1.99(1.57-2.51) <0.001 ***
MDD - Bipolar 1.49(0.62-3.60) 0.491  
Never Smoked Ref Ref Ref
Currently Smoke 1.54(1.31-1.82) <0.0001 ***
Ex Smoker 1.38(1.19-1.59) <0.0001 ***
SIMD – Most deprived quintile 1.30(1.06-1.60) 0.026 *
SIMD – 2nd quintile 1.15(0.95-1.40) 0.245
SIMD – 3rd quintile 1.10(0.90-1.34) 0.458
SIMD – 4th quintile 0.99(0.83-1.19) 0.951  
SIMD – Least deprived quintile Ref Ref Ref 
Neuroticism 1.12(1.10-1.15) <0.0001 ***
SPQ 1.03(1.01-1.05) 0.002 *
g 0.90(0.85-0.94) <0.0001 ***
No physical health complaints Ref Ref Ref
1-2 physical health complaints 1.25(1.09-1.44) 0.004 *
3+ physical health complaints 2.05(1.45-2.89) <0.0001 ***
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Table S4: Crude and Age-Sex Reweighted Prevalence of Antidepressants in Generation Scotland 2010-2016
Antidepressant 
Prevalence
2010 2011 2012 2013 2014 2015 2016
All 
antidepressants 
Crude 13.9(13.3-
14.6)
14.8(14.2-
15.5)
15.7(15.0-
16.4)
16.3(15.6-17.0) 17.1(16.4-17.9) 17.8(17.1-
18.5)
18.3(17.6-
19.1)
Age-Sex 
Reweighted
12.7(12.0-
13.5)
13.7(13.0-
14.5)
14.4(13.6-
15.2)
15.0(14.2-15.8) 16.0(15.2-16.9) 16.5(15.7-
17.4)
17.3(16.5-
18.3)
Exc. low dose 
amitriptyline
Crude 11.0(10.5-
11.6)
11.7(11.1-
12.3(
12.5(11.8-
13.1)
12.7(12.1-13.4) 13.4(12.8-14.1) 14.1(13.5-
14.8)
14.7(14.0-
15.4)
Age-Sex 
Reweighted
9.9(9.3-
10.6)
10.6(9.9-
11.2)
11.3(10.7-
12.0)
11.7(11.0-12.5) 12.4(11.7-13.2) 12.9(12.3-
13.7)
13.9(13.1-
14.7)
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Table S5 : Medications that previously antidepressant naïve (n=1250) antidepressant users 
in GS:SFHS were first commenced on during the entire period studied 2009-2016
Mechanism of 
action*
Antidepressant 
class
Number of 
individuals
%
Amitriptyline Reuptake inhibitor (SERT and 
NET), receptor antagonist (5-
HT2)
TCA 37 3.0
Citalopram Reuptake inhibitor (SERT) SSRI 499 39.9
Duloxetine Reuptake inhibitor (SERT and 
NET)
SNRI 31 2.5
Fluoxetine Reuptake inhibitor (SERT) SSRI 270 21.6
Mirtazapine Receptor antagonist (NE 
alpha-2, 5-HT2, 5-HT3)
Other 87 7.0
Nortriptyline Reuptake inhibitor (NET) TCA 49 3.9
Paroxetine Reuptake inhibitor (SERT) SSRI 5 0.4
Sertraline Reuptake inhibitor (SERT) SSRI 177 14.2
Tranylcypromine Enzyme inhibitor (MAO-A and 
-B), releaser (DA, NE)
MAOI 0 0
Venlafaxine Reuptake inhibitor (SERT and 
NET)
SNRI 19 1.5
Lofepramine Reuptake inhibitor (NET and 
SERT)
TCA 9 0.7
Trazodone 
hydrochloride
Reuptake inhibitor (SERT), 
receptor agonist (5-HT1A), 
receptor antagonist (5-HT2)
Other 22 1.8
Agomelatine Receptor agonist (Mel1,Mel2), 
receptor antagonist (5-HT2B, 
5-HT2C)
Other 0 0
Clomipramine 
hydrochloride
Reuptake inhibitor (SERT, 
NET (metabolite))
TCA 4 0.3
Dosulepin 
hydrochloride
Reuptake inhibitor (SERT and 
NET)
TCA 11 0.9
Doxepin Reuptake inhibitor (NET and 
SERT), receptor antagonist 
(5-HT2)
TCA 4 0.3
Escitalopram Reuptake inhibitor (SERT) SSRI 12 1.0
Flupentixol Receptor antagonist (D2, 5-
HT2)
Other 1 0.1
Fluvoxamine maleate Reuptake inhibitor (SERT) SSRI 0 0
Imipramine 
hydrochloride
Reuptake inhibitor (SERT and 
NET)
TCA 13 1.0
Mianserin 
hydrochloride
Receptor antagonist (alpha-
2), reuptake inhibitor (NET)
TCA 0 0
Moclobemide Reversible enzyme inhibitor 
(MAO-A)
MAOI 0 0
Phenelzine Enzyme inhibitor (MAO-A and 
-B)
MAOI 0 0
Reboxetine Reuptake inhibitor (NET) Other 0 0
Trimipramine Receptor antagonist (5-HT2 
and D2)
TCA 0 0
Tryptophan Essential amino acid, precursor to 
5-HT and Me
Other 0 0
* = source : Neuroscience-Based nomenclature http://www.nbn2.org/ [Accessed 26-10-18]
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Abbreviations :   SERT = serotonin transporter. 5-HT = 5-hydroxytryptamine/serotonin. NE=noradrenaline. NET = noradrenaline transporter. 
DA/D=dopamine. Me=Melatonin. MAO=monoamine oxidase.   SSRI=selective serotonin reuptake inhibitor.                       TCA=tricyclic 
antidepressant. MAOI=monoamine reuptake inhibitor. SNRI=selective serotonin and noradrenaline reuptake inhibitor. 
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Table S6
Part A : Sensitivity Analysis of Medication Possession Ratio (MPR) per Antidepressant 
Episodes During 5 Year Period 2012-2016 With Cut-Off Point Between Episodes Varying 
Between 60 and 360 Days 
Cut-Off 
Point 
Between 
Episodes 
Individuals Prescribing 
Episodes 
(2012-2016)
Mean 
Duration
(days)
Median 
Duration
(days)
Min MPR
(%)
MPR 
1Q
(%)
MPR 
Median
(%)
MPR 
Mean
(%)
MPR 3Q
(%)
Max MPR
(%)
60 2385 4370 526 231 10.9 90.3 100 99.3 103.4 411.8
90 2385 3595 679 307 10.6 86.5 99.1 96.3 100.5 411.8
120 2385 3280 777 372 11.7 84.9 98.1 95 101.1 411.8
150 2385 3117 839 411 11.7 83.5 97.4 94 100.7 411.8
180 2385 3008 891 452 11.7 82.2 96.6 93.2 100.7 411.8
270 2385 2813 997 557 11.7 79.9 95.7 91.4 100.4 283.7
360 2385 2707 1064 654 11.7 77.8 94.7 90 100 283.7
Part B : Sensitivity Analysis of Proportion of Days Covered (PDC) per Antidepressant 
Episode During 5 Year Period 2012-2016 With Cut-Off Point Between Episodes Varying 
Between 60 and 360 Days 
Cut-Off 
Point 
Between 
Episodes 
Individuals Prescribing 
Episodes
(2012-16)
Mean 
Duration
(days)
Median 
Duration
(days)
Min 
PDC
(%)
PDC 
1Q
(%)
PDC 
Median
(%)
PDC 
Mean
(%)
PDC 
3Q 
(%)
PDC 
Max
(%)
% Adherent 
PDC
60 2385 4370 526 231 10.7 80.3 88.9 87.4 100 100 76
90 2385 3595 679 307 10.6 77 86.3 84.9 99.3 100 69
120 2385 3280 777 372 5.8 74.4 85.1 82.7 96.9 100 64.6
150 2385 3117 839 411 3.1 72.3 84.5 81.4 96.3 100 61.7
180 2385 3008 891 452 3.1 70.4 83.6 80.1 95.5 100 59.3
270 2385 2813 997 557 3.1 65.9 82.2 77.6 94.5 100 55.5
360 2385 2707 1064 654 3.1 62.3 81.1 75.9 93.3 100 52.8
Part C : Comparison of Proportion of Days Covered for Antidepressant Episodes involving 
Different Medication Classes (SSRI, TCA, SNRI, MAOI, Other) and Different Previous 
Histories of Affective Disorder on GS:SFHS Recruitment 
Group Cut-Off 
Point 
Between 
Episodes
Individuals Mean 
Duration
(days)
Median 
Duration
(days) 
Min PDC
(%)
PDC 1Q
(%)
PDC 
Median
(%)
PDC 
Mean
(%)
PDC 
3Q 
(%)
PDC 
Max
(%)
% Adherent 
PDC  (>= 80% 
PDC)
SSRI 90 1924 672 326 1 76.7 85.8 84.5 96.8 100 68.1
TCA* 90 422 937 488 1 76.8 85.5 84.3 100 100 67.8
SNRI 90 310 1120 931 25.7 76.3 84.2 83.2 90.8 100 67.3
MAOI 90 14 1251 1110 52.4 71 77.1 77.3 82.7 100 31.3
Other 90 414 908 522 28.5 76.8 85 83.9 94.1 100 65.9
MDD 
history: 
Bipolar 
disorder
90 29 813 568 62.9 72.9 81.8 83.5 94.2 100 56.3
Recurrent 
MDD
90 421 968 576 23.2 76.1 84.7 83.3 92.3 100 66.1
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For Peer Review
11
No MDD 
history
90 1611 578.9 265.5 10.6 77.7 87.4 85.5 100 100 70.3
* = TCA  - excluding low dose amitriptyline 
Abbreviations : MPR = Medication Possession Ratio. 1Q=1st quartile. 3Q=third quartile. MDD = major depressive disorder. 
MPR=medication possession ratio. PDC=proportion of days covered. 
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